Investigation and Management of Epidemic-Prone Diseases In Ethiopia

Awala Equar, R.N., B.Sc., M.P.H.; Azarias Assefa, M.D.; Dawit Shawel, B.Sc., M.Sc.; and Seifu Hagos, B.Sc., M.P.H.

Mekelle University

In collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education

June 2007
PREFACE

Manuals which entirely focus on epidemic investigation and management of epidemic prone diseases in the context of the country are scarce or if present may only provide concepts and ideas limited to a single disease outbreak. Thus, students, instructors and health professionals might be forced to search other materials/references for different outbreaks/epidemics when they are in need. This manual may reduce the problem of limited access to information on the principles of outbreak investigation, preparedness and response, management and monitoring of epidemic prone diseases in Ethiopia.

This manual is prepared primarily for health science and medical students in universities. However, such manuals are not also available at regional health professional training institutions and health facilities. Different categories of health workers who are working in these facilities directly or indirectly
engaged in investigation and management of epidemics/outbreaks would be benefited from such material.

Investigation of infectious disease outbreaks are commonly encountered in Ethiopia, and findings of such investigations are often published; however, surprisingly little has been written about the actual steps followed during such investigations and the detailed activities in the process. This manual, thus, attempts to outline the general approach to conduct an outbreak investigation, management along with investigation of specific infectious diseases of public health importance and the investigation of outbreaks in special settings.

The primary motivation to write this manual came from the dire scarcity of practical manuals for health science and medical students to acquire the knowledge and skill of conducting outbreak investigation and management in the country. In addition, the same shortage of practical manuals for health workers and the very limited reference material for outbreak investigation in different settings
have also inspired the authors to write this manual with the support of Ethiopia Public Health Training Initiative of The Carter Centre.

The first chapter gives an overview of occurrence of disease and types of epidemics. The second chapter draws on the background given in chapter one and highlights and expatiates on the activities in epidemic investigation. In the same chapter management of epidemic is mentioned as one step leaving the detailed discussion of Epidemic management for the following chapter. Among the components of epidemic management, epidemic preparedness and response will make the initial part of chapter 3, followed by control measures during epidemics in the later part. Monitoring and evaluation of epidemic response is discussed in chapter 4. After all general principles have exhaustively been done, Chapter 5, then proceeds to the discussion of Epidemic investigation and management of specific epidemic prone diseases. Finally epidemic investigation and management in different special settings will be
discussed in the last chapter followed by important Annexes.
ACKNOWLEDGEMENTS

We would like to thank the Ethiopia Public Health Initiative (EPHTI), The Carter Center for providing financial and advisory support in the development of this Manual. We would like also to thank Ato Yohannes Tewelde and Ato Berhane Haileselassie for their effort and contribution during the intra review process. We would like to extend our appreciation to Dr. Anwar Yibire, Ato Lemissa Olijirra, Dr. Nigusse Deyassa, Captain Sintayehu Teshome, Dr. Zelealem Kebede, for their valuable contribution and critical review of the material before and during the inter university review.

We are deeply grateful to Professor Ahmed Ali and Professor Yemane Berhane for their contribution in reviewing and providing valuable and detailed comments that helped us to enrich the manual.

We would like to extend our appreciation to the staff in Mekelle University, College of Health Sciences that
facilitated the process of the preparation of this Manual.
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHI</td>
<td>Avian Human Influenza</td>
</tr>
<tr>
<td>AI</td>
<td>Avian Influenza</td>
</tr>
<tr>
<td>BCG</td>
<td>Bacille Calmette-Guerin</td>
</tr>
<tr>
<td>CFR</td>
<td>Case Fatality Rate</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebro Spinal Fluid</td>
</tr>
<tr>
<td>DDT</td>
<td>Dichlorodiphenyl trichloro-ethane</td>
</tr>
<tr>
<td>DHN</td>
<td>Dehydration</td>
</tr>
<tr>
<td>DOB</td>
<td>Date of Birth</td>
</tr>
<tr>
<td>DOT</td>
<td>Direct Observed Therapy</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EPHTI</td>
<td>Ethiopian Public Health Training Initiative</td>
</tr>
<tr>
<td>EPI</td>
<td>Expanded Program on</td>
</tr>
</tbody>
</table>

vii
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunization</td>
<td>Human Immuno-deficiency Virus</td>
</tr>
<tr>
<td>HIV</td>
<td>Health Information Management Systems</td>
</tr>
<tr>
<td>IC</td>
<td>Infection Control</td>
</tr>
<tr>
<td>IDSR</td>
<td>Integrated Disease Surveillance and Response</td>
</tr>
<tr>
<td>IgM</td>
<td>Immuno-Globulin M</td>
</tr>
<tr>
<td>IP</td>
<td>Incubation Period</td>
</tr>
<tr>
<td>IM</td>
<td>Intra-Muscular</td>
</tr>
<tr>
<td>IU</td>
<td>International Unit</td>
</tr>
<tr>
<td>IV</td>
<td>Intra-Venous</td>
</tr>
<tr>
<td>MDR</td>
<td>Multi-Drug Resistant</td>
</tr>
<tr>
<td>NGOs</td>
<td>Non-Governmental Organizations</td>
</tr>
<tr>
<td>NNT</td>
<td>Neonatal Tetanus</td>
</tr>
<tr>
<td>ORS</td>
<td>Oral Rehydration Solution</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PO</td>
<td>Per Os</td>
</tr>
<tr>
<td>RF</td>
<td>Relapsing Fever</td>
</tr>
<tr>
<td>SD</td>
<td>Shigella Dysentariae</td>
</tr>
<tr>
<td>SMX</td>
<td>Sulpha-Methoxazole</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TMP</td>
<td>Trimethoprin</td>
</tr>
<tr>
<td>TT</td>
<td>Tetanus Toxoid</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>i</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>v</td>
</tr>
<tr>
<td>List of abbreviations</td>
<td>vi</td>
</tr>
<tr>
<td>Table of contents</td>
<td>x</td>
</tr>
<tr>
<td>List of tables and figures</td>
<td>xv</td>
</tr>
<tr>
<td>Chapter One: Occurrence of disease and emergence of epidemics</td>
<td>1</td>
</tr>
<tr>
<td>1.1 Learning objectives</td>
<td>1</td>
</tr>
<tr>
<td>1.2 Introduction</td>
<td>1</td>
</tr>
<tr>
<td>1.3 Definition of common terms</td>
<td>2</td>
</tr>
<tr>
<td>1.4 Types of epidemic</td>
<td>7</td>
</tr>
</tbody>
</table>
Chapter Two: Principles of epidemic investigation and preparedness for response

2.1 Learning objectives 10
2.2 Introduction 10
2.3 Activities in outbreak investigation 14

Chapter Three: Principles of epidemic management

3.1 Learning objectives 46
3.2 Introduction 47
3.3 Activities in epidemic management 48
3.4 Epidemic control measures 57

Chapter Four: Monitoring and evaluation of epidemics/outbreaks

4.1 Learning objectives 65
4.2 Introduction 66
4.3 Performance monitoring and evaluation 67
4.4 Monitoring and evaluation frameworks 70
4.5 Indicators of performance monitoring and evaluation for epidemic investigation and management 73
4.6 Data system in monitoring and evaluation of epidemic control 75

Chapter Five: Management of epidemic-prone diseases in Ethiopia 79

Learning objectives 79
Introduction 79
5.1 Bloody diarrhea 81
5.2 Cholera 87
5.3 Malaria 92
5.4 Measles 98
5.5 Meningitis 104
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.6 Relapsing Fever</td>
<td>114</td>
</tr>
<tr>
<td>5.7 Typhoid Fever</td>
<td>118</td>
</tr>
<tr>
<td>5.8 Epidemic (louse-borne) Typhus</td>
<td>122</td>
</tr>
<tr>
<td>5.9 Visceral Leishmaniasis (Kala-azar)</td>
<td>125</td>
</tr>
<tr>
<td>5.10 Yellow Fever</td>
<td>130</td>
</tr>
<tr>
<td>5.11 Avian Human Influenza</td>
<td>133</td>
</tr>
<tr>
<td><strong>Chapter Six: Management of outbreaks in special settings</strong></td>
<td>144</td>
</tr>
<tr>
<td>6.1 Epidemics in school settings</td>
<td>144</td>
</tr>
<tr>
<td>6.2 Epidemics in prison settings</td>
<td>149</td>
</tr>
<tr>
<td>6.3 Epidemics in hospital settings</td>
<td>165</td>
</tr>
<tr>
<td>6.4 Epidemics associated with disasters</td>
<td>171</td>
</tr>
<tr>
<td><strong>References</strong></td>
<td>176</td>
</tr>
<tr>
<td><strong>Annexes</strong></td>
<td>183</td>
</tr>
<tr>
<td>Annex 1. Outline for preparing epidemic preparedness and response plan</td>
<td>183</td>
</tr>
</tbody>
</table>
### Epidemic Prone Diseases

<table>
<thead>
<tr>
<th>Annex</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annex 2. Treatment of diarrhea</td>
<td>185</td>
</tr>
<tr>
<td>Annex 3. Treatment of malaria</td>
<td>189</td>
</tr>
<tr>
<td>Annex 4. Setting a threshold for malaria</td>
<td>194</td>
</tr>
<tr>
<td>epidemic/preparing a norm-chart</td>
<td></td>
</tr>
<tr>
<td>Annex 5. Specimens for laboratory确认 for epidemic-prone diseases</td>
<td>198</td>
</tr>
<tr>
<td>Annex 6. Recommended case definitions for use by health facilities and by community</td>
<td>201</td>
</tr>
<tr>
<td>Annex 7. IDS case-based surveillance reporting format</td>
<td>205</td>
</tr>
<tr>
<td>Annex 8. Case study: Epidemic preparedness and response plan for measles outbreak</td>
<td>211</td>
</tr>
</tbody>
</table>

**Glossary**  
230
## LIST OF TABLES

| Table 5.1. Antibiotic drugs of choice to treat bloody diarrhea due to S. dysentariae type 1 | 85 |
| Table 5.2. Antibiotic drugs of choice to treat cholera | 90 |
| Table 5.3. Recommended vitamin A schedule for measles treatment | 104 |
| Table 5.4. Standard treatment of meningitis in urban area | 111 |
### LIST OF FIGURES

<table>
<thead>
<tr>
<th>Fig.</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Epidemic curve for point source epidemic</td>
<td>30</td>
</tr>
<tr>
<td>1.2</td>
<td>Epidemic curve for point source (upper), continuous common source (middle) and propagated epidemic (lower)</td>
<td>34</td>
</tr>
<tr>
<td>1.3</td>
<td>Spot map showing distribution of cases by place</td>
<td>40</td>
</tr>
<tr>
<td>3.1</td>
<td>Outbreak detection and response without preparedness</td>
<td>59</td>
</tr>
<tr>
<td>3.2</td>
<td>Outbreak detection and response with preparedness</td>
<td>60</td>
</tr>
<tr>
<td>4.1</td>
<td>Logical framework of monitoring and evaluation for epidemic control activities</td>
<td>72</td>
</tr>
</tbody>
</table>
CHAPTER ONE

OCCURRENCE OF DISEASE
AND TYPES OF EPIDEMICS

1.1 Learning Objectives: At the end of this chapter, the student will be able to:

- define common terms related to disease occurrence;
- identify Epidemic and types of Epidemic;
- describe the steps in the investigation of an outbreak/epidemic;
- describe the different approaches of outbreak management.

1.2 Introduction

Diseases occur in a community at different levels at a particular point in time. Some diseases are usually present in a community at a certain predictable level; this level is called the expected level.
Terms for occurrence of disease at expected level include:
- Endemic,
- Hyper/hypo/meso- endemic
But at times diseases may occur in excess of what is expected.
Terms for occurrence of disease at excess of the expected level include:
- Epidemic - Pandemic
  - Outbreak - Cluster
A term for irregular and occasional occurrence of disease:
- Sporadic

1.3 Definition of common terms
a. Occurrence of disease at expected level include:
An endemic disease is a disease that occurs in a population with predictable regularity and with only minor deviations from its expected frequency of occurrence. It is vital to note that a disease may be
endemic in a population at any frequency level, provided that it occurs with predictable regularity. Additional terms can be used to describe endemic diseases according to their frequency of occurrence:

- **Hyperendemic** is an endemic disease that affects a high proportion of the population at risk.
- **Mesoendemic** is an endemic disease that affects a moderate proportion of the population at risk.
- **Hypoendemic** is an endemic disease that affects a small proportion of the population at risk.

b. **Occurrence of disease at excess of the expected level include**

**Epidemic** refers to the occurrence of disease or health related condition in excess of the usual frequency in a given area or among a specified group of people over a particular period of time.

The following points are worth noting.

- The term epidemic can refer to any disease and health related condition
E.g. Epidemic of Measles, epidemic of obesity, epidemic of drug addiction, epidemic of rape etc

- The minimum number of cases that fulfills the criteria for epidemic is not specific and the threshold may vary
  - E.g. One case of Small pox or Avian Human Influenza may constitute an epidemic

- Knowledge of the expected number is crucial to label an occurrence of a particular event as an epidemic
  - Excess occurrence will have no meaning if there is no known expected level

- The expected level varies for different diseases and different geographic locations.
  - E.g. The expected level of Tuberculosis in Ethiopia and USA is very different and hence what constitutes an epidemic in each set up will be different
**Outbreak** is an epidemic of shorter duration covering a limited area. It is usually used interchangeably with Epidemic.

E.g. Outbreak of gastroenteritis after sharing a common meal at an event

A **cluster** is an unusual aggregation of health events in a given area over a particular period. The emphasis in case of a cluster is aggregation in a certain locality than the actual number of cases. For instance, three or four cases of a certain illness might occur in a certain kebele, while no cases occur in all other kebeles of a certain district. In this case, the number of cases might not be sufficient to constitute an epidemic. But, the occurrence in the particular kebele may be better referred to as a ‘cluster’.

Other examples include: the cluster of cases of cholera in London investigated by John Snow, the cluster of cases of Angiosarcoma (a rare liver cancer) in workers of one factory led to identification of vinyl chloride as potent carcinogen.
**Pandemic** is an epidemic involving several countries or continents affecting a large number of people.  
E.g. - the influenza pandemic  
- the HIV pandemic

c. **Irregular and occasional occurrence of disease**

**Sporadic** refers to occasional or irregular occurrence of disease.  
A *sporadic* disease is a disease that is normally absent from a population but which can occur in that population, although rarely and without predictable regularity.  
Examples of endemic, epidemic and sporadic occurrences of disease

The following diseases are examples of endemic diseases in Ethiopia: malaria, schistosomiasis, chronic hepatitis, trachoma, scabies, malnutrition, amoebiasis, tuberculosis and typhus. Among the above diseases malaria and typhus frequently occur as epidemic when the environment or the host favours their occurrence. Cholera, yellow fever and
meningococcal meningitis often occur as epidemics in Ethiopia. Examples of sporadic diseases in Ethiopia include colonic cancer, Parkinson’s disease, etc.

1.4. Types of epidemic

Three types are well recognized:
- Common source
- Propagated/progressive and
- Mixed.

1.4.1. Common source epidemics

Common source epidemic is a type of epidemic caused by exposure of a group of people to a common risk factor, such as an infectious agent or a toxin or a chemical, etc.

This can take two forms:

i- Point source epidemic

- If the exposure is brief and simultaneous, all exposed will develop the disease within one incubation period – referred to as point source epidemic/outbreak. Example: food borne
outbreak of Acute Gastro Enteritis in attendants of a wedding feast.

ii- Continuous/ Intermittent common source

- If the source of an outbreak remains for a longer time, days, weeks or longer either continuously or intermittently, it is called Continuous or intermittent common source epidemic. A waterborne outbreak that is spread through a contaminated community water supply can be an example.

1.4.2. Propagated or progressive epidemics

Outbreak of this type occurs from transmission of an infectious agent from one susceptible an infected host to another. It can be through:

- Direct person-to-person transmission or
- Indirect transmission: through a vector, vehicle, etc.

Examples: epidemics of measles, yellow fever, malaria, etc.
1.4.3. Mixed Epidemic

Mixed epidemics is an epidemic which shows the features of both types of epidemics (common and propagated). It usually begins with a common source of infectious agent with subsequent propagated spread, e.g. most food borne outbreaks.
CHAPTER TWO
INVESTIGATION OF OUTBREAKS

2.1 Learning Objective: At the end of this chapter, the student will be able to:

- understand how outbreaks are recognized;
- reason out why outbreaks are investigated;
- describe the steps in the investigation of an outbreak/epidemic.

2.2 Introduction

Outbreak investigation is a method for identifying and evaluating people who have been exposed to an unusual occurrence of disease or other health problems. It is an important component of epidemiology and public health, which through a systematic way helps in identifying the source of
ongoing outbreaks and in preventing additional cases. Outbreak investigation is, however, a challenging task for a number of reasons. First there is great urgency to find out the source and prevent additional cases and also a substantial pressure to conclude rapidly, particularly if the outbreak is ongoing, which may lead to hasty decisions regarding the source of the outbreak with negative consequences on the success of control measures. Second the involvement of many agencies and the fact that outbreak investigation is carried out at many levels pose a threat to undertake a well coordinated work. In many outbreaks, the number of cases available for study is limited; therefore, the statistical power of the investigation is also limited.

**How are outbreaks recognized?**

Possible outbreaks of disease come to the attention of public health officials in various ways.

a. Review of routinely collected surveillance data can detect outbreaks of known diseases, through regular analysis and interpretation, if
there is a strong and quality surveillance system in place
b. Often, observant clinicians, infection control nurses, or clinical laboratory workers first notice an unusual disease or an unusual number of cases of a disease and alert public health officials.
c. Frequently, it is the patient (or someone close to the patient) who first suspects a problem, as is often the case in food borne outbreaks after a shared meal
d. Sometimes public health officials learn about outbreaks of disease from the local newspaper or television news.

Why are Outbreaks Investigated?

a. The most compelling reason to investigate a recognized outbreak of disease is that exposure to the source(s) of infection may be continuing; the investigation provides helpful information to take immediate action i.e. by identifying and eliminating
the source of infection, we can prevent additional cases.
b. Because the results of the investigation may lead to recommendations or strategies for preventing similar future outbreaks, thereby improving long term disease prevention activities.
c. Other reasons include:
   i. to describe new diseases and learn more about known diseases;
   ii. to evaluate existing prevention strategies, e.g., vaccines;
   iii. to address public concern about the outbreak.

**When should outbreaks be investigated?**
For some communicable diseases, a single suspected case might suffice to start the process of investigation. For instance, diseases with a potential for massive epidemics or diseases caused by etiologic agents of high virulence need more attention and alertness than others. Such diseases need
immediate investigation followed by immediate response. For example, viral hemorrhagic fevers,

For some other diseases, the investigation is initiated when a certain threshold is passed, or when an unusual increase in the number of deaths due to a certain cause is noticed during analysis of surveillance data or when a cluster of deaths due to unknown cause is seen.

2.3 Activities in outbreak investigation?

There is no rigid step to follow during investigation of an outbreak. Several activities could be accomplished simultaneously. The steps to follow are set by the individual investigator depending on the suspected cause of the outbreak.

1. Verify that there is an epidemic
2. Prepare to conduct an investigation
3. Construct a suspected case definition
4. Collect laboratory specimens and obtain laboratory results
5. Search and record additional cases while managing the already identified cases
6. Describe the epidemic with respect to time, place, person
7. Formulate hypothesis about the cause of the epidemic and test them
8. Reach at final decision based on all the available evidences
9. Intervene (take action)
10. Report and disseminate findings

2.3.1. Verify that there is an epidemic
Reports about presence of epidemics are not always correct and one of the crucial tasks in epidemic investigation is verifying whether there is really an epidemic or not. This is particularly important when considering the resources that would be expended for an artifactual rise in the number of cases or deaths.
a. Verifying the diagnosis in the index case/s
In order to verify the suspected epidemic, one might start by verifying the diagnosis in the index case(s). This is done by reviewing clinical and laboratory findings in index cases to establish diagnosis.

NB: Index case(s) is/are the first case(s) to come to the attention of health authorities. Index cases are important because they indicate the possible start of an outbreak; the sooner the index case and other early cases are identified and diagnosed, the higher the chance of arresting the epidemic. However, it should be noted that the notion of index cases might not be valid in case of diseases which normally occur at a predictable regularity and that occasionally occur in excess of their expected frequency.

b. Compare current occurrence with the expected occurrence:
The other essential task of verifying an epidemic is to compare the current number of cases with the past levels of disease in that community, considering the seasonal variation in the occurrence of the disease.
This will help in determining whether an excessive number of cases have occurred or not.

c. Rule out artifactual changes in the occurrence of the disease:
Even if there seems to be an apparent excess in the number of cases or deaths due to a disease, still potential causes of a false-rise exist and should be looked for. These include:
  - a change in case detection (e.g. more or less accurate diagnostic facility)
  - a change in a case definition or reporting
  - a change in the denominator

In majority of instances, partly because of incomplete data, the investigator might not be certain whether the existence of the epidemic is real or not. In such situations, the following three considerations should be done in order to declare an epidemic.
i. **Is there a risk for wider transmission if left without intervention?**
For example, diseases like viral hemorrhagic fever pose a serious threat to the public because of extremely high risk for disease wider transmission in contrast to diseases like neonatal tetanus which pose less threat to the public.

ii. **How severe is the disease?**
The consequence of overlooking a real epidemic of a mild viral skin rash with only minimal sequels might be far more acceptable than overlooking a viral encephalitis with proven fatal cases.

iii. **Are resources available to effect a plausible intervention?**
For example, in an area where there are no vaccines for Mumps, outbreak investigations might not result in proper actions.

### 2.3.2. Prepare to conduct further investigation

Once the investigator decides to conduct an outbreak investigation for the verified epidemic, the next logical
step is to make the necessary preparations to launch further investigation.

**a. Search and gather scientific information necessary for the outbreak investigation:**

No single investigator is fully knowledgeable about all diseases, and health problems which need investigation and appropriate ways of investigating and managing their outbreaks. Each outbreak investigator, therefore, should always update him/her self with the necessary scientific knowledge both about the nature of the disease to be investigated and also about the scientifically proven or sound methods of investigating and managing the outbreaks. This includes collecting sample questionnaires, discussing with experienced people, reading applicable literatures, etc.

**b. Make important communications:**

As is often the case, there are people and units of governmental organizations responsible for investigating and/or managing epidemics. Identify
these people and communicate with them to plan the investigation and management together. For example, using the already available data and with discussion with responsible persons, decide where to undertake the investigation taking the most affected geographical location as a starting place for the outbreak investigation.

c. Establish an outbreak investigation and management team
For a smooth execution of outbreak investigation and management, it is helpful to establish a team with clearly defined roles. In situations where there is epidemic preparedness, there will already be identified team members who will take part in the investigation and management as well. Team members should be well aware of their specific roles in the process of investigating the outbreak. In addition the team should plan and decide how communication among the team members will go during the outbreak investigation.
d. Develop data collection tool for the outbreak investigation

The investigation team should develop data collection tool relevant for the health problem under investigation. For example the following variables and information might be important regardless of the disease under investigation:

- Identifying information: inclusion of names, address, etc allows investigators to contact patients and to map the geographic extent of the problem (spot map analysis).
- Socio-demographic information: includes age, sex, marital status, occupation, educational status, religion, income etc provides the "person" characteristics of the population at risk.
- Clinical and lab information: includes symptoms, signs, date of onset, results of laboratory tests etc and allows verification of the case definition and charting the time course of the outbreak, and helps to describe the spectrum of the illness.
- Risk factor information: include inquiries made to elicit specifically exposure to the suspected
cause(s), e.g. contact with people with similar illness, travel history, immunization status etc.

e. Make administrative arrangements
This part of the preparation should not be neglected, as it is one of the major factors affecting success of outbreak investigations. Beginning from the start of the epidemic investigation, investigators should plan for adequate transportation, personnel, equipment and logistic supplies. For example, most outbreak investigations entail laboratory materials (e.g. serologic kits); every effort should be made to obtain essential materials well in advance of the beginning of the actual investigation activities.

2.3.3 Construct a suspected Case definition
Case definition is a set of criteria for deciding whether an individual should be classified as having the condition of interest. A suspected case definition includes clinical and epidemiologic criteria , (i.e. general description of the type of disease and description of the disease by Place, Person and
Time), and is used to identify all possible cases associated with the outbreak. Since case definitions used at this initial stage of the outbreak investigation lack specificity, they are labeled as suspected case definitions. Likewise, the cases identified are also referred to as suspected cases.

Example of suspected case definitions: fever, with or without vomiting, chills, myalgia, (for an Acute Febrile Illness), a new onset of diarrhea (It is worth noting that standard suspected case definitions are available for most epidemic prone priority diseases. Making efforts to find these standard case definitions saves time and prevents bad consequences a poorly constructed case definition.

2.3.4 Collect laboratory specimens and obtain laboratory results

Laboratory tests are mandatory for most epidemics of infectious diseases, for the purpose of confirming diagnosis in the individual patient and also understanding the cause of the epidemic. Laboratory investigations usually include:
A. Microscopic demonstration or isolation by culture of the agent

B. Serologic studies (done two times, 4 weeks apart)

Based on additional information laboratory results, the cases who fit the suspected case definition can be classified as confirmed, probable, or possible.

- **Confirmed/definite**: a case with laboratory verification.
- **Probable**: a case with typical clinical features of the disease without laboratory confirmation.
- **Possible**: a case presented with fewer of the typical clinical features.

Throughout the outbreak investigation, steady quality assurance together with checkup of congruence between clinical findings and laboratory results should be made. For this, communication between laboratory persons and clinicians is very crucial. However, it should be remembered that for many health facilities laboratory investigation of every case can not be practical for obvious reasons. In
such situations, it might suffice to conduct laboratory tests for the first few cases of the disease. For example, taking serum samples for the first 5 cases is recommended for measles.

It has to be also noted that laboratory tests may include environmental investigations, i.e. investigation of food sanitation, suspected breeding sites, animal reservoirs according to the type of the disease being investigated. In fact, it is the result from the findings of the epidemiological investigation that guides the collection and testing of environmental samples. Example: Samples of foods and beverages served at a common meal believed to be the source of an outbreak of gastroenteritis should be investigated after a clue from epidemiologic results.

**2.3.5 Search and record additional cases while managing the already identified cases**

The presence of some identified cases at a certain health facility often imply that there are cases which are yet unidentified, that there are cases yet to be
symptomatic, and that there are individuals yet to be exposed to the risk factor of the disease under investigation. Thus, active search for additional cases is extremely vital if the investigation is to prevent healthy people from contracting the disease.

This is done by:

a. **Passive surveillance:**

   This includes:

   - Searching similar cases in the registers of health facilities where cases have been reported.
   - Recording each case fulfilling the suspected case definition on the reporting format prepared for the investigation. The case reporting format should include identifying information, socio-demographic information, clinical and lab information, risk factor information.
b. **Active surveillance:**

This includes:

- Sending out a letter describing the situation and asking for reports.

- Alerting the public directly, to see a physician if they have symptoms compatible with the disease in question.

- Asking case-patients if they know anyone else with the same condition.

- Conducting an active case-finding mission.

Meanwhile, cases of the disease that are already identified should get the appropriate treatment preferably by following standard case management guidelines. Hand in hand with this, the necessary precautions for preventing disease transmissions in health facilities should be in order.
2.3.6 Describe the epidemic with respect to time, place, person

Using stimulated passive surveillance and active surveillance for recording identified cases, there will be available data for analysis by important variables. These variables are Time, Place and Person. The purpose of describing disease occurrence by time, place and person is to get a clue about the general features of the epidemic (where are most cases of the epidemic seen, where is epidemic spreading to, what the source of the epidemic is, who the high risk groups are, etc) so that early and timely measures can be started. Therefore, analysis of data should be done frequently during the epidemic as new data might change the findings of the description.

a. Characterize the outbreak by time: Epidemic curve

The epidemiologic tool for describing disease occurrence by time is called epidemic curve. Epidemic curve is a graph commonly a histogram,
showing the distribution of cases plotted over time. The date of onset of each case is depicted by the horizontal axis while the number of cases corresponding to each date of onset is shown on the vertical axis.

Several important information can be obtained from studying the epidemic curve:

i. The type of epidemic
ii. Probable date of exposure
iii. Probable etiologic agent
iv. Timeliness of detection

i. **Type of the epidemic:** point source, continuous/intermittent common source, propagated.

An epidemic curve which shows a rapid rise and fall (also called log-normal distribution) suggests a point source epidemic or an outbreak caused by simultaneous exposure of a group of people to a common risk factor, such as an infectious agent or a toxin or a chemical for a brief period. The epidemic curve often starts and ends within a single incubation period. Example: food borne outbreak of Acute Gastro Enteritis in attendants of a wedding feast. An
exception to the rapid rise and fall of a point source epidemic is when the incubation period of the disease is long. Example: the curve for point source epidemic of Hepatitis A will not be the typical log-normal distribution.

**Figure 1.1**: Epidemic curve for point source epidemic

- a = minimum incubation period (from time of exposure to the onset of the 1st case)
- b = duration of the outbreak (from time onset of 1st case to the time of onset of the last case)
• $c =$ mode of the incubation period (from the time of exposure to the date with maximum onset of cases)

• $a + b =$ maximum incubation period (from the time of exposure to the date of onset of last case)

On the other hand in cases of continuous or intermittent common source epidemic (i.e. the source of an outbreak remains for a longer time, days, weeks or longer either continuously or intermittently as in cases of a waterborne outbreak that spreads through a contaminated community water supply) the epidemic curve will have no clear peak (wider or irregular) and will be with prolonged duration of more than 1 incubation period. This is because there will be multiple exposures with variable incubation periods unlike in that of the point source epidemic.

If the epidemic is propagated or progressive type (i.e. transmission of an infectious agent from one susceptible host to another either through direct or indirect transmission e.g. epidemics of measles,
yellow fever, malaria, etc), typically, the epidemic curve would have:

- An initial slow rise (showing few people infected spread)
- A succession of several peaks (showing the presence of several generations of cases and increased number of cases in each generation)
- A prolonged duration (more than 1 incubation period)
- A sharp fall (showing either a critical reduction in the number of susceptible individuals or effect of intervention measures)

However, in reality, few propagated outbreaks provide a classic pattern. For instance, epidemics of highly infectious diseases with short incubation period can create a rapidly rising and falling epidemic curve similar to that of a point source epidemic. Example: influenza.
The Point Source
Cases from a single brief exposure
Figure 1.2: Epidemic curve for point source (upper), continuous common source (middle), and propagated epidemic (lower).
ii. Probable date of exposure

The time till the date of mode of the epidemic curve is taken as the average incubation period of the etiologic agent. In case of point source epidemic, an epidemic curve can be used to determine the probable date of exposure if the etiologic agent is known.

- Date of exposure = Date of the mode - the average IP

iii. The probable etiologic agent

In a point epidemic, the epidemic curve can also be used to identify the etiologic agent if the date of exposure is known.

- Average IP = Date of the mode - Date of exposure

This is possible because most infectious agents have relatively unique duration of incubation periods and by determining the average incubation period it is possible to guess what the causative agent of the epidemic was.
Exercise:
An outbreak caused by certain etiologic agent X, with an incubation period of 2-15 days (average 8 days), has the following characteristics:

- Date of onset of the first case: September 20, 2005
- Date of onset of the last case: September 30, 2005
- Date on which the greatest number of cases had their onset: September 25, 2005

i. Is this a point source epidemic? Why?
   ii. Estimate the probable date of exposure.

In case of the above outbreak, the duration of the outbreak (from September 20 up to September 30) was less than the maximum incubation period of the etiologic agent. In other ways, the epidemic was limited within one incubation period and in such cases, the most probable type of epidemic is point source epidemic.

The probable date of exposure can be calculated in two ways
• One method is by subtracting the minimum incubation period from the date of onset of the first case (September 20 minus 2 days) or by deducting the maximum incubation period from the date of onset of last case (September 30 minus 15 days). This gives us September 18 (from the first) and September 15 (from the second); the probable date of exposure was between September 15 and 18.

• The other method is by subtracting the average incubation period from the date on which maximum number of onsets is recorded (the mode). This means September 25 minus 8 days, which gives the probable date of exposure to be on September 17.

Though the above two methods gave different results, the results are nearly the same and can be used as an estimate of the date on which there was exposure causing the outbreak.
iv. Evaluation of the timeliness of detection, investigation and response

In addition to the date of onset of each case, the horizontal axis of the epidemic curve can also be made to show the following dates:

- date of case detection of the index case(s)
- date of report of the possibility of the epidemic to the investigator(s)
- date when the investigation was began
- date when the response was began

Using the distance from the onset of illness in the index case(s), one can determine the level of awareness of the community about the disease under investigation, the timeliness of the report from the health institution, the timeliness of the response from the investigator(s), the timeliness of measures taken, etc.

b. Characterize the outbreak by place, spot map

Description of the epidemic by place is also another very vital task which potentially uncovers several features of the epidemic. The epidemiologic tool for
describing epidemics by place is called spot map. Spot map is a map showing the case of a disease in their respective place of residence. However, the spot map is only a display of the number of cases in the respective localities; it doesn’t take in to consideration the population density difference of each sub area. It is therefore important to supplement spot maps with place specific attack rates particularly if there is a perceived variation in the population density.

In the spot map: pay particular attention to:

- Cluster of cases or deaths
- Relation of clusters with presumed sources of infection (for e.g. common water source)

Another application of spot map is when one cannot distinguish the two (common source and propagated) by the epidemic curve, studying the geographic distribution will help to differentiate them. The propagated epidemics tend to show geographic spread with successive generations of cases in the spot map while the common source epidemic tend to aggregate in certain places.
Fig. 1.3. Spot map showing distribution of cases by place.
c. Characterize the outbreak by person, person specific attack rates

Identifying personal characteristics that could be related with the cause of the epidemic also gives valuable clues about the epidemic and the high risk groups. For instance some of the intervention measures for all practical reasons couldn't be given for each and every individual in the affected areas. For example vaccinations are seldom plenty to give them for all people in the area. Therefore identifying the high risk group makes issuing interventions feasible in addition to unraveling helpful clues as to the cause of the epidemic.

Some of the personal characteristics include (depending on the type of the disease):

- Age
- Sex
- Occupation
- Pertinent travel history
- Urban or Rural residence
- Immunization status
- Inpatient and outpatient status
- Outcomes of cases (Survived/died)
- Laboratory results

The rate of disease occurrence given by the above specific personal characteristics is called person specific attack rate. For example, Sex specific attack rate.

2.3.7 Formulate hypothesis about the cause of the epidemic and test them

The data obtained from the description of the epidemic by place, person and time can be used to formulate a hypothesis about the cause of the epidemic. The formulated hypothesis can be tested using either of the two methods:

- The attack rate method
- The case-control method

These methods allow the identification of the possible sources of the epidemic by quantifying the strength of association between exposure and disease.
i. The attack rate method

Attack rate (incidence rate) is calculated for two group of individuals: those exposed to the risk of interest and with out the risk.

\[
\text{Attack rate} = \frac{\text{new cases of disease during the outbreak}}{\text{Total Population at risk of contracting the disease}} \times 100
\]

The greater the difference in attack rates in people exposed and not exposed to a suspected exposure, the stronger the evidence that the particular exposure is the cause of the disease. It is worth noting that information is needed both from example: those exposed to the risk factors of interest and those without. It is a common pit fall to leave those without the risk.

ii. The case control method

Cases and non cases are compared with respect to the proportion of people exposed. The greater the difference in proportion of cases exposed and non-cases exposed, the stronger implication of association between the exposure and the disease. It
is worth noting that information is needed both from cases and non-cases to determine the cause. During outbreak investigation, concentrating only on the cases might mislead to a wrong conclusion about the cause. Both cases and non-cases have to be analyzed if one wishes to know the exposure that has the strongest relation with the disease.

**NB:** In both methods of analysis, *tests of statistical significance* are needed to show that the difference in attack rate between exposed and non exposed people, or in the proportion of exposed people between cases and non cases, are statistically significant and not the result of chance variation.

Presence or absence of association between exposure and disease should not be taken ultimate; it needs confirmation by isolation of etiologic agent from remnants of the sources (e.g. food items in case of food borne outbreaks) or other strong evidences that the exposure is the source of the outbreak.
2.3.8 Reach at a final decision based on all the available evidences

This step of the investigation should come up with the source of the agent, the mode of transmission, and the exposures that caused the disease. The hypothesis testing is used as one major evidence but all the other evidences including disease description, laboratory investigation and other scientific facts are used to reach at a decision about the answers for the above important questions.

2.3.9. Take control measures/intervene (see next chapter)

2.3.10. Report and disseminate findings (see next chapter)
CHAPTER THREE
PRINCIPLES OF EPIDEMIC MANAGEMENT

3.1. Learning objectives: At the end of this chapter, the student will be able to:

• explain the importance of epidemic preparedness and response plan;
• describe the objectives of epidemic preparedness and response plan;
• describe the component of epidemic preparedness and response plan;
• understand the aim of control measures of an epidemic;
• know the appropriate timing of control measures of epidemics;
• describe the different approaches of outbreak management.
3.2. Introduction

The advance in the development of specific plans in epidemic preparedness and response are crucial for early epidemic/outbreak detection and response and to maintaining the viability of epidemic investigation and management (Fig 3.1 and 3.2). This section outlines elements of preparedness and response; anticipation/prediction, early detection, rapid and effective response. These include establishing epidemic preparedness and response committee, set priority, formulate epidemic preparedness and response plan, implement surveillance and respond rapidly and effectively and also underlines the need to work closely with community to formulate practical guidelines which will be the central part of epidemic investigation and management.

Such plans must be integrated into each community and facility's emergency response plans like Disaster preparedness and response plan and Early warning system and should be adaptable to potential
3.3. Activities in epidemic management

Management of epidemics should include preparing, responding, and evaluating the management of epidemics.

3.3.1. Epidemic preparedness and response

Objectives

The objective of epidemic preparedness and response are:

- To anticipate/predict the occurrence of epidemic so that epidemics can be prevented;
- For early detection of epidemic that helps to know when there is a problem;
- To establish rapid response through guidelines/trained staff/supplies and in place before epidemic; and
- To have effective response with appropriate control method and adequate resources and logistics.

Components of epidemic preparedness and response
The major components of epidemic preparedness and response plan are to establish epidemic preparedness and response committees, setting priority, formulate epidemic preparedness and response plan, implement/strengthen surveillance and respond rapidly and effectively.

A. Establish Epidemic preparedness and response Committee
The key to an effective epidemic investigation and response is to establish co-ordination between all players should at the national, zonal, district and kebele level based on the availability of technical staffs (physicians, epidemiologists, microbiologists, public health officers, health educators, environmental health workers, authorities and the
community representatives). The best way to ensure this is to establish an epidemic management committee early in the epidemic. This team can then co-ordinate all the activities. It must function on a continuous basis, and meet periodically even when no epidemics are present.

The following points should be considered during establishment:

- Members of the committee may vary according to the levels (national, zonal, district and kebele) and mainly include technical staffs, political leader, community representative and other governmental and non-governmental agencies.

- Tasks of the committee classified before, during and after the occurrence of the epidemic.
Before the epidemic, the committee members should:

- Set priorities
- Write the epidemic preparedness and response plan
- Define prevention and control strategies
- Ensure that the surveillance system can detect epidemic occurrences
- Assign specific responsibilities for surveillance, preparedness, and response
- Identify and mobilise resources

During the epidemic, the committee members should:

- Implement the plan (verification, investigation and management of the epidemic)
- Rapid and co-ordinated response
- Implement prevention and control strategies
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

- Monitoring and evaluation of prevention and control strategies
- Identify, mobilise and utilize available resources
- Reporting

After the epidemic, the committee members should:
- Evaluate the preparedness and response
- Review and update the plan
- Modify prevention and control strategies
- Identify and mobilise resources
- Anticipate new epidemic
- Strengthen surveillance

B. Setting priorities
Before setting the priority, the following questions should be answered based on literature review, report, health institution records…etc.
- What are the major epidemic prone diseases?
- What is the risk of an epidemic?
Time since last outbreak, example one may suspect meningitis outbreak if there has been outbreak free period of two years as it is usual for meningitis to occur every two years these times.

Frequency of previous outbreaks and recent disease trends, e.g. if Cholera outbreaks are occurring in a country frequently, the risk for further epidemic clearly great.

What would be the likely impact of an epidemic?
- Potential number of cases
- Potential deaths and disabilities
- Likelihood of spread
- Economical and Social impacts
- Are effective and affordable control measures available?
- Do we have adequate resources/human power, drug supply, money…etc?
C. Formulate epidemic preparedness plan

The plan should include the following:

- List the priority diseases
- Define the surveillance, preparedness and response measures to be implemented
- Identify responsibilities (who does what)
- Identify co-ordination mechanisms (leadership)
- Specify resources available for preparedness and response (budget)
- Decide on the list of activity, resources or supplies that will be required for the activity and time framework

D. Implement/strengthen surveillance

Successful epidemic response depends on effective surveillance system. Hence, during the acute phase of the epidemic it is necessary to keep the individuals at special risk (e.g. contacts) under surveillance. After the epidemic is under control, it becomes necessary to keep the community under surveillance
to detect further rises in incidence and to ensure the effectiveness of the selected control measures. The best surveillance method is one which keeps all links of the chain (infectious agent, reservoir, route of transmission and levels of immunity) under close scrutiny. Early detection of a recurrence of the epidemic will enable it to be limited to the smallest number of victims.

The sources of information which can be utilised for surveillance are initially, notifications of illness by medical staff, community health workers, employers of labour, school teachers, heads of families; secondly certification of deaths by medical authorities; and thirdly, data from other sources such as community members.

Reporting from the sources listed may be inadequate and a special surveillance team may be needed while the threat continues. Staffs engaged in surveillance are trained in the early accurate recognition of the disease, or in identification of the causative agent.
The Core function of surveillance should include:
- Systematic data collection
- Investigation & confirmation
- Analysis & interpretation
- Response
- Reporting

The Support function of surveillance should include:
- Training
- Supervision
- Resource
- Standards/guidelines

### 3.3.2. Respond rapidly and effectively to epidemics

The aim of epidemic response is to contain the epidemic and reduce morbidity and mortality. For having a rapid and effective response during epidemic investigation and management, the following activities should be an integral part of the epidemic preparedness and response plan.
These activities are:

- Early and regular epidemic preparedness and response team/committee meeting
- Early assessment of the potential scale of the epidemic
- Co-ordinated investigation and implementation of control measures
- Providing public information when ever important using health education and media strategy

3.4. Epidemic control measures

3.4.1. Aim of control measures

Central to any outbreak investigation is the timely implementation of appropriate control measures to minimize further illness and death. The aim of all control measures is to act at the weak link or links in the chain of infection (or any exposure outcome chain) so as to prevent additional cases of the illness. However, the type of control measures which would be taken is dependent on the type of the specific diseases and this is discussed in detail in chapter 5.
3.4.2. The timing of control measures

At best, the implementation of control measures would be guided by the results of the epidemiologic investigation and possibly (when appropriate) the testing of environmental specimens. However, this approach may delay prevention of further exposure to a suspected source of the outbreak and is, therefore, unacceptable from a public health perspective. Therefore, for most outbreaks of illnesses, intervention must start as soon as the minimum adequate information about the outbreak is gathered.

On the other hand, because the recall of a food product, the closing of a restaurant or similar interventions can have profound economic and legal implications for an institution, a manufacturer or owner, and the employees of the establishments involved, acting precipitously can also have substantial negative effects.
The timing and nature of control measures are difficult. Balancing the responsibility to prevent further disease with the need to protect the credibility and reputation of an institution is very important.
3.4.3. General classes of interventions

Control measures for every of infectious diseases of public health importance are different and relatively peculiar, however most of the intervention measures can be grouped into three:

i. Measures directed against reservoirs
   - If reservoirs of the disease include domestic animals immunization, testing of herds and
destruction of infected animals, example: brucellosis and bovine tuberculosis

- If the reservoirs are wild animals like in case of Rabies, post-exposure prophylaxis is the recommended measures
- If humans are the main reservoirs of infection, the following are potential control activities:
  - Removal of the focus of infection, e.g. cholecystectomy for typhoid carriers
  - Treatment of infected individuals to make them non infectious; e.g. Tuberculosis
  - Isolation of infected persons from the non-infected for the period of communicability

NB:
- Isolation is not suitable for the control of diseases in which a large proportion of infections are inapparent or in which maximal infectivity precedes overt illness.
- Quarantine is a form of isolation with limitation of freedom of apparently healthy persons or animals who have been exposed to a case of
infectious diseases. It is usually imposed for the duration of the usual maximal incubation period of the disease. Cholera, Plague and Yellow fever are the three internationally quarantable diseases by international agreement.

- Now quarantine is replaced in some countries by active surveillance of the individuals – maintaining close supervision over possible contacts of ill persons to detect infection or illness promptly; their freedom of movement is not restricted.

ii. Measures that interrupt the transmission of organisms

Interruption of transmission of organisms may include the following activities:

- Action to prevent transmission of disease by ingestion includes purification of water, pasteurization of milk, inspection procedures to ensure safe food supply, improve housing conditions
• Attempts to reduce transmission of respiratory infections include chemical disinfection of air & use of ultra violet light, improving ventilation patterns.

• Action to interrupt transmission of disease whose cycles involve an intermediate host: E.g. clearing irrigation farms from snails to control Schistosomiasis.

iii. Measures that reduce host susceptibility
Control measures also include strengthening the host’s immunity to resist disease through the following activities:

• Active immunization, e.g. in the prevention of EPI disease
• Passive immunization, e.g. Tetanus, Rabies
• Chemoprophylaxis, e.g. Tuberculosis, Malaria

3.4.4. Report and disseminate findings
At the end of epidemic investigation, prepare a comprehensive report and submit to the
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

appropriate/concerned bodies. The report should discuss in detail:

- Factors leading to the epidemic.
- Evaluation of measures used for the control of the epidemic.
- Recommendations for the prevention of similar episodes in the future.

Dissemination of findings through mass media, channels directed at health workers, and professional journals can be done as appropriate and giving feedback.
CHAPTER FOUR
MONITORING AND EVALUATION OF EPIDEMIC INVESTIGATION AND MANAGEMENT

4.1 Learning objectives
At the end of this chapter the student will be able to:
• describe the basics of planning for performance monitoring and evaluation of epidemic investigation and management;
• acquainted with components of performance monitoring and evaluation of epidemic investigation and management;
• describe monitoring and evaluation frameworks, indicators and health management information system for Epidemic investigation and management; and
• evaluate the timeliness of detection, investigation and response status.

4.2 Introduction

At the end of the epidemic it is important to evaluate the various phases of the response and to prepare a report of the epidemic and lessons learnt. Monitoring and evaluation of the epidemic through continued surveillance to determine if there is further spread and the impact of interventions.

The purpose of Monitoring and Evaluation of epidemic is to measure effectiveness. Ideally, Monitoring and Evaluation tools can be used to demonstrate that efforts have truly had measurable impacts on the outcomes of interest i.e. in the control of epidemics. In other situations, monitoring and evaluation can indicate whether resources are being used most efficiently.

Monitoring tools are those used to track ongoing results in epidemic control activities. Evaluation tools, on the other hand, are used to assess or to analyze
the impact of control activities in order to understand the conditions that help or hinder their success. Hence monitoring and evaluation helps to:

- make informed decisions regarding operations management and service delivery;
- ensure the most effective and efficient use of resources;
- determine the extent to which epidemic control activities are on track and to make any needed corrections accordingly and helps in objective conclusions about the extent to which the epidemic control activities is having or has had the desired impact.

4.3 Performance Monitoring and Evaluation

Performance monitoring is tracking the key elements of epidemic control activities performance over time (inputs, activities, results). Evaluation is used to measure changes in targeted results that can be attributed to the intervention, or analyzing inputs and
activities to determine their contribution to averting the epidemic. In other words, evaluation activities go beyond the scope of the control activities to consider, and sort out the influence of other factors. For instance, members of the community who live in the suspected area may not be applying the preventive and control measures for the reason of negligence. Monitoring may reveal that the number of cases of the suspected epidemic is increasing, but it will require an evaluation activity to reveal why the numbers of cases are still increasing, and then the control activities may perhaps be adjusted to measures that are locally acceptable.

Performance monitoring, hence can:

- Indicate whether the control activity is being implemented as planned
- Identify changes over time in inputs, outputs, and some outcomes
- Indicate problems that may be resolved while the control is ongoing and suggest problem areas and possible solutions
Performance Evaluation can:

- Identify changes in the pattern of epidemic over time
- Indicate the extent to which observed changes are the result of the control /intervention/

Components of performance monitoring and evaluation plans
Planning for monitoring and evaluation is crucial and requires the allocation of adequate resources (time, money, personnel, materials and equipment). Monitoring and evaluation of epidemic control plans should typically include the following components:

- Underlying situations regarding the local context. These situations are time/period, socio-culture, economic contexts, settings, organization of the community, availability of media etc…
- Well-specified conceptual measures and operational definitions. These include case definitions for detection, case management
protocols, indicators and metric), along with baseline values, monitoring schedule, data sources for the monitoring and evaluation, and resource estimates

- Anticipated relationships between control activities, targets, and outcomes
- Specific attention to periodic evaluation and use of epidemic control performance indicators, clearly defining indicators and data systems
- Discussion of evaluation plans and plans for using monitoring and evaluation results, possibly including dissemination, be incorporated into ongoing decision-making to improve outcomes.

4.4 Monitoring and evaluation Frameworks

Frameworks are best understood as useful tools for understanding and analyzing a control program, which are crucial for developing and implementing sound monitoring and evaluation plans. Designing
frameworks is one way to develop a clear understanding of the goals and objectives of the control activities with emphasis on the objective or measurable objectives. Developing monitoring and evaluation frameworks also help to clearly define the relationships among factors key to the implementation and success both internal and in interaction with the external environment or context. In other words, developing frameworks help generate a clear picture of ideal goals and objectives, and the elements both within and external operations that will affect its success in the particular context. This design process deepens the understanding of managers, implementers, and other partners in many practical ways, including serving as the foundation for selecting appropriate, useful monitoring and evaluation indicators.
Fig. 4.1. Logical framework of monitoring and evaluation for epidemic control activities

- Inputs
  - Epidemic preparedness and response plan
  - Personnel
  - Time
  - Finance
  - Materials and supply

- Processes
  - Conduct outbreak detection
  - Outbreak investigation
  - Outbreak confirmation
  - Organize responses
  - Involving the community
  - Information management

- Output
  - Outbreak detected
  - Outbreak confirmed
  - Responses organized
  - Community actively involved
  - Determinants identified
  - Cases managed
  - Other measures specific to the epidemic taken

- Outcome
  - Decreased number of reported cases
  - Reduction of morbidity and mortality

Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia
4.5 Indicators of performance monitoring and evaluation for epidemic investigation and management

The above logical framework enables to formulate monitoring and evaluation indicators. An indicator is a variable that measures one aspect of a program or project. The purpose of indicators typically is to show that a program activity has caused a change or difference in something else. Therefore an indicator of that change will be something that we reasonably expect to vary. Its value will change from a given or baseline level at the time the intervention starts, to another value after the intervention has had time to make its impact felt, when the variable, or indicator, is calculated again. Secondly, an indicator is a measurement. It measures the value of the change in meaningful units for program management that can be compared to past and future units and values. In other words, calculation of an indicator establishes the objective value at a point in time with a metric for some factor of interest to program goals. Even if the
factor itself is subjective, like attitudes of a target population, the indicator metric calculates its value objectively at a given time. Thirdly, an indicator focuses on a single aspect of a program or project. It may be an input, an output, or an overarching objective, but its related indicator will be narrowly defined in a way that captures that aspect as precisely as possible. A full, complete, and appropriate set of indicators for a given project or program in a given context with given goals and objectives will include at least one indicator for each significant element of the intervention. An indicator as shown in the logical framework can be:

**Input indicators:** - the number and type of personnel, the amount of money allocated etc.

**Process indicators:** - outbreak detection, confirmation and control (the quality of early warning system, flow of epidemiological information, laboratory confirmation of the diagnosis, case definition, case management, education campaigns, surveillance, others
Output indicators: are those indicators which inform how effectively epidemic control is carried out from case detection until case management.

Outcome indicators: decreased number of reported cases over twice the incubation period of the problem in question, reduced mortality from the cause.

How many indicators are enough?

- At least one or two indicators per result (ideally with different data sources)
- At least one indicator for every activity, no more than ten or fifteen indicators per area of significant program focus. Try to include a variety of data collection activities or sources.

4.6 Data system in monitoring and evaluation of epidemic control

After formulating monitoring and evaluation indicators, a clearly defined and strong data system shall be established. The system will have the following characteristics:
- It will have an appropriate range and number of clearly operationalized indicators,
  
  - It will draw on a variety of appropriate data sources and kinds of data;
  
  - It will include baseline and target values appropriate for the program in its particular Operational context, for each indicator; and
  
  - It will spell out a plan and schedule for data collection, including estimations of the financial and technical resources that will be required to achieve each element of that plan, in such a way that all stakeholders are aware of and commit to their share of responsibility for ensuring the Data System functions as designed.

Monitoring and evaluation of epidemic investigation and management vary according to which level it serves. These may include:

  - Policy or Program Level
  - Population Level
  - Service Environment Level
The data sources for the monitoring and evaluation for epidemic investigation and management may come from:

- Case surveillance (e.g., epidemiology of disease)
- Medical records
- Interview data
- Sentinel surveillance systems
- Sample households or individuals

Tools for monitoring and evaluation of epidemic investigation and management include:

- Case reports
- Client register analysis
- Patient flow analysis
- Direct observation
Data Quality Issues related to monitoring and evaluation of epidemic investigation and management:

- Will the data cover all of the elements of interest? (Coverage)
- Is there a complete set of data needed for each element of interest? (Completeness)
- Have the instruments been tested to ensure validity and reliability of data?

Data Quality Issues:

- Are the data collected as frequently as needed? (Frequency)
- Does the available data reflect the time periods of interest (Reporting Schedule)
- Can the data needed from each source be collected/retrieved? (Accessibility)
CHAPTER FIVE
EPIDEMIC-PRONE DISEASES
AND THEIR MANAGEMENT IN
ETHIOPIA

Learning objectives: At the end of this chapter, student will be able to:

• Describe the epidemiological characteristics of the common (epidemic-prone) diseases;
• Describe the risk/precipitating factors for occurrence of outbreaks of different epidemic-prone diseases;
• Describe the case definitions for different epidemic-prone diseases;
• Describe the investigation and management activities of epidemics of different diseases.

Introduction
Among the communicable diseases included in the integrated disease surveillance system in the
country, 11 of them are under the list of diseases labeled as epidemic-prone. However, this manual has included those epidemic-prone diseases that are known to cause epidemics in the country. These include cholera, bloody diarrhea (shigella), measles, meningitis, yellow fever, typhoid fever, relapsing fever, epidemic typhus and malaria. In addition, leishmaniasis (kala-azar) and avian human influenza are included to increasing attention they are given at national level.

In this chapter, epidemiology and characteristics of each of the specific disease, risk factors, case definition, epidemic investigation and management procedures of the respective diseases are briefly presented.
5.1 Bloody diarrhea

Epidemiology and Characteristics of the disease

Bloody diarrhea has been ranked among the top 10 causes of morbidity in under five children in Ethiopia. Its occurrence is widespread throughout Ethiopia and is associated with outbreaks. Bloody diarrhea is caused by bacteria including shigella, E. coli, non-typhoid salmonella, campylobacter jejuni. It is also caused by E. hystolytica.

Shigella dysenteriae is the most common cause of enteric infections. Large-scale epidemics may be caused by shigella dysentariae type 1(SD1) with up to 30% of the population infected. The case fatality rate may approach 20% among young children and elderly persons with severe dehydration and in state of malnutrition. The incubation period is from 1 to 4 days.

Clinical illness is characterized by acute fever and bloody diarrhea and can also present with systemic
symptoms and signs as well as dehydration especially in young children.

Transmission: Shigella dysentriae is transmitted from person-to-person through fecal-oral spread.

Favoring transmission:
Overcrowded areas with unsafe water and poor sanitation (for example, refugee and famine population).

Case definition
Suspected case:
A person with diarrhea and with visible blood in stool.

Confirmed case:
Suspected case with stool culture positive for shigella dysentariae 1.

Investigation
- Interrogate the case to determine factors contributing to transmission.
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

- Obtain stool or rectal swab specimen for confirming the epidemic.

**General Management**

- Report the suspected case to the next higher level of the health system.
- Search for additional cases in locality of confirmed case.
- Mobilize community to enable rapid case detection and treatment.
- Identify high-risk populations using person, place, time data.
- Reduce sporadic and epidemic-related cases by promoting hand washing with soap or ash and water after defecating and before handling food, strengthening access to safe water supply and storage, and use of latrines and safe disposal of human waste.
Specific management

- Assess patient for dehydration and rehydrate with oral rehydration solution or I.V fluids accordingly (annex 2.1) and
- Treat suspected case with antibiotics based on recent susceptibility results, if available; drugs of choice include Nalidixic acid or Ciprofloxacin or Cotrimoxazole.
Table 5.1. Antibiotic drugs of choice to treat bloody diarrhea due to S. dysentariae type 1

<table>
<thead>
<tr>
<th>Weight</th>
<th>Nalidixic acid (Give four times daily for 5 days)</th>
<th>Ciprofloxacin (Give two times daily for 5 days)</th>
<th>Cotrimoxazole (trimethoprim + sulphamethoxazole) (Give two times daily for 5 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet</td>
<td>Tablet 250 mg</td>
<td>Tablet 250 mg</td>
<td>Adult tablet 80 mg TMP + 400 mg SMX</td>
</tr>
<tr>
<td>mg</td>
<td></td>
<td></td>
<td>Pediatric tablet 20 mg TMP + 100 mg SMX</td>
</tr>
<tr>
<td>Children'</td>
<td></td>
<td></td>
<td>Syrup 40 mg TMP + 200 mg SMX per 5 ml</td>
</tr>
<tr>
<td>s dose</td>
<td>3-5 kg</td>
<td>6-9 kg</td>
<td>10-14 kg</td>
</tr>
<tr>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td>1/4</td>
<td>1/2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>1/4</td>
<td>1/2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>1/4</td>
<td>1/2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>5.0 ml</td>
<td>7.5 ml</td>
<td>7.5 ml</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
5.2 Cholera

**Epidemiology and Characteristics of the disease**
Cholera is an acute illness with profuse rice watery diarrhea caused by bacteria called Vibrio Cholerae.

Cholera causes over 100,000 deaths per year. It may produce rapidly progressive epidemics or worldwide pandemics. The incubation period is from a few hours to 5 days, usually in the range from 2 to 3 days. Cholera may cause severe dehydration in only a few hours. About three-fourth of individuals infected with V. cholera are asymptomatic. Another 20% show mild diarrhea that cannot be distinguished from other causes of diarrhea. It is 2-5% of individuals infected with V. cholera that show the severe form of the disease. The case fatality rate (CFR) may exceed 50% in untreated patients with severe dehydration. If patients present at the health facility and correct treatment is received, the CFR is usually less than 1%. At least 90% of the cases are mild.
Transmission: It is transmitted mainly through eating or drinking contaminated food or water; that is, cholera is spread through the fecal-oral route.

Determinants:

Environmental factors:
- Areas without safe and adequate water supply
- Areas without good sanitation
- Seasonality not well understood

Host factors:
- Persons with gastric achlorhydria

The organism:
- Only serogroups 01 and 0139 cause epidemics; other serogroups can cause diarrhea, but not epidemics

Case definition

Suspected case (where cholera is not known to be present): Any person aged 5 years or more, who develops severe dehydration or dies from acute watery diarrhea.
Confirmed case of cholera: Any person with diarrhea who has V. cholera 01 or 0139 isolated from their stool.

Investigation

- Maintain surveillance through watching for increase in the baseline number of cases of cholera in endemic areas and be alert for a single case in non-endemic area.
- Obtain laboratory confirmation
- Investigate suspected cases

General management

- Convene epidemic committee
- Inform the public concerning the need to seek appropriate treatment without delay
- Implement control measures
  - Health education on safe drinking water, hand washing, food safety, and seeking treatment early.
  - Provision of safe and adequate water
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

- Safe disposal of excreta
- Disposal of bodies and disinfection
- Collect and report data/document epidemic

Specific management

- Assess patient for dehydration and rehydrate with oral rehydration solution or I.V fluids accordingly (annex 2.1) and
- Treat suspected cases of cholera with antibiotics using recommended drugs. Drugs of choice are listed in the table below.

Table 5.2. Antibiotic drugs of choice to treat cholera

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxycycline</td>
<td>---</td>
<td>300 mg</td>
</tr>
<tr>
<td>Tetracycline (4 times per day for 3 days)</td>
<td>12.5 mg/kg</td>
<td>500 mg</td>
</tr>
<tr>
<td>Trimethprim-sulfamethoxazole (twice a day for 3 days)</td>
<td>TMP 5 mg/kg and SMX 25 mg/kg</td>
<td>TMP 160 mg and SMX 800 mg</td>
</tr>
<tr>
<td>Furazolidone (4 times</td>
<td>1.25 mg/kg</td>
<td>100 mg</td>
</tr>
</tbody>
</table>
Erythromycin 10 mg/kg (3 times per day for 3 days) 250 mg (4 times per day for 4 days)

Doxycycline is WHO’s antibiotic of choice for adults (except pregnant women) because only one dose is required.

TMP-SMX is WHO’s antibiotic of choice for children. Tetracycline is equally effective, but may not be available for pediatric use in some countries. Furazolidone is the antibiotic of choice for pregnant women.

Use erythromycin or chloramphenicol if the other recommended antibiotics are not available, or where V. cholera strains are resistant to them.
5.3 Malaria

Epidemiology and Characteristics of the disease
Malaria is one of the most serious and complex health problems of human beings. It causes 300 million to 500 million episodes of acute illness and 1.2 million deaths per year globally. It is the leading cause of death in children under 5 years in sub-Saharan Africa and, in some countries, accounts for one quarter of such deaths.

Malaria is a major public health problem in Ethiopia. It has been consistently reported as one of the three leading causes of morbidity and mortality in the past years. The magnitude of the problem in 2002/2003 has even worsened and the disease has been reported as the first cause of morbidity and mortality accounting for 15.5% out-patient consultation, 20.4% admissions and 27.0% in patient deaths. In non-epidemic year, 5-6 million clinical malaria cases and over 600,000 confirmed cases are reported from health facilities.
Malaria is caused by protozoan parasites of the genus Plasmodium. Four species of plasmodium can produce the disease in its various forms—Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae. P. falciparum is the most widespread and dangerous of the four: untreated it can lead to fatal cerebral malaria.

**Transmission:** Parasites are transmitted from one person to another by the female anopheline mosquito. Incubation period varies with the type of plasmodium species, mostly 7-14 days.

**Epidemic precipitating factors:**
Possible precipitating factors of malaria epidemics include:

a) Increase in vectorial capacity, e.g. importation of a more potent vector.

b) Natural increase, mainly through abnormal rainfall (usually excess, sometimes deficit). Other factors may be elevation in temperature and humidity.
c) Man-made increase: deterioration of vector control operations, inadequate management of surface waters, increased irrigation and other development activities, insecticide resistance, destruction of cattle and/or houses (e.g. through disaster or war) leading to increase man/vector contact.

d) Immigration of non-immune into an endemic area.

e) Immigration of infective into a receptive non-endemic area.

f) Resistance to anti malarial drugs.

Case definition

Uncomplicated malaria:
Any person with fever or fever with headache, back pain, chills, sweats, myalgia, nausea, and vomiting diagnosed clinically as malaria.
Confirmed uncomplicated malaria:
Any person with fever or fever with headache, back pain, chills, sweats, myalgia, nausea, vomiting and with laboratory confirmation of diagnosis by malaria blood film or other diagnostic test for malaria parasites.

Severe malaria
Any person hospitalized with a primary diagnosis of malaria and confirmed by a positive blood smear or other diagnostic tests for malaria.

Investigation
• An epidemic should be suspected when there is an unusual increase in the number of new malaria cases or deaths compared to the same period in previous non-epidemic years.
• Use “Norm-chart” or a threshold level to detect a possible epidemic. A threshold level is established using the 3rd quartile of a 5 years period of time (see annex 3).
• Prepare necessary tools to collect data about the occurrence of the disease.
• Gather supplies (rapid diagnostics test kits, slides, pricking needle) for collecting laboratory specimens.
• Collect laboratory specimens (blood smear) and obtain the results.

General management
• Provision of early diagnosis and prompt treatment to all people who are sick.
  Initiate active surveillance of cases.
• Source reduction/control of larval stages by sanitary improvements that will result in reduction of anopheline mosquito breeding habitats.
• Reduce the risk of mosquito bites (using insecticide treated nets, indoor residual spraying).
Specific management

- Artemether-lumefantrine is the first line of treatment of P. falciparum administered for 3 days. For infants less than three months or five kg of body weight and pregnant women in the first trimester, oral quinine administered 3 times a day for 7 days.

- If a P. falciparum positive patient returns back to facility with fever or history of fever between the 4th day and 14th day after treatment with Artemether-Lumefantrine, do blood examination for malaria parasites. In addition, ask the patient if he/she has vomited the drug or had diarrhea after treatment. Check also whether the drug taken is of reliable brand and is not expired. If the blood film is positive for asexual malaria parasites and other conditions are excluded, administer oral quinine if condition of the patient permits.
5.4 Measles

Epidemiology and Characteristics of the disease
Measles is a febrile rash illness due to paromyxovirus (morbillivirus). Measles virus is spread via the respiratory route and is transmitted extremely efficiently. Measles is characterized initially by fever, cough, runny nose, and malaise, making it indistinguishable from many other viral respiratory infections for the first several days, during which the child is highly infectious. A characteristic rash then appears. The incubation period is 7 to 18 days from exposure to onset of fever.

Before widespread use of measles vaccine, measles was consistently one of the leading causes of death among children worldwide, accounting for an estimated 20-30% of such deaths. Large epidemics occur every few years in areas with low vaccine
coverage and where there is an accumulation of persons who have never been infected or vaccinated. The World Health Organization estimates that measles still causes 45 million cases and 1 million child deaths, with over 50% of these in Sub-Saharan Africa.

**Transmission:** Airborne by droplet spread and direct with nasal or throat secretions of infected persons.

**Determinants:**
- In the absence of vaccination, every child in an area where measles virus is circulating would be expected to contract measles.
- Living in overcrowded urban areas.
- Large family size, travel patterns, and types and locations of social interactions (for example, market-places).
- Immuno-compromized individuals
Case definition:
Suspected case:
Any person with fever and maculopapular (non-vesicular) generalized rash and cough, coryza or conjunctivitis (red eyes) OR any person in whom a clinician suspects measles.

Confirmed case:
A suspected case with laboratory confirmation (positive IgM antibody) or epidemiological link to confirmed cases in an epidemic.

Threshold level for epidemic: 5 cases per week in a health facility.

Investigation
- Report suspected case to the next level.
- Collect blood sample for confirming the epidemic.
- Investigate the case or epidemic to identify causes of epidemic.
General management

- Improve routine vaccine coverage through the EPI, and lead supplemental vaccination activities in areas of low vaccine coverage.
- Isolation of children or should be kept out of school at least 4 days after appearance of the rash.

Specific management

a. Case management of uncomplicated measles

Many children will experience uncomplicated measles and will require only supportive measures:

- Give vitamin A, first dose in the health facility or clinic; give the mother one dose to give at home the next day.
- Advise mothers to treat the child at home as long as no complications develop
- Provide nutritional support: continue breast feeding or give weaning foods and fluids at frequent intervals and treat mouth ulcers
- Control fever by keeping the child cool
• Instruct to return for further treatment if the child's general condition worsens or any of the danger signs develop.

• Explain to mothers that there is an increased risk of diarrhoea, acute respiratory infections and other infections in the weeks following measles and encourage them to seek medical advice early.

• Immunize close contacts, if they are identified within 72 hours of exposure.

Supplementary measles immunization should focus on areas not yet affected, but where the outbreak is likely to be spread. Start immunization immediately.

Target age group: during epidemics the recommended age to be included in the supplemental immunization is 6 months to 5 years. Depending on the attack rate, children older than 5 years can be consider (e.g. school-age children).
b. Case management of complicated measles

In developing countries, at least three-quarters of cases can be expected to have at least one complication and some may have multiple systems involvement.

Actions to be taken in cases of complication include:

- refer to health facility for further management
- follow the above recommendations for case management of uncomplicated measles

AND

- ensure that two doses of vitamin A are given
- clean eye lesions and treat with 1% tetracycline eye ointment three times a day for 7 days (for corneal lesions, cover the eye with a patch) - vitamin A administration is particularly important to minimize the risk of potentially blinding eye lesions: in this situation, use a third dose of vitamin A four weeks later using the same dosage and age as in table 2.
- clean ear discharge and treat with antibiotics
• refer suspected encephalitis to hospital
• treat malnutrition and diarrhoea with sufficient fluids and a high quality diet considering availability at local level.
• treat pneumonia with antibiotics.

Table 5.3. Recommended Vitamin A Schedule for measles treatment

<table>
<thead>
<tr>
<th>Age</th>
<th>Immediately on Diagnosis</th>
<th>Next Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant &lt; 6 months</td>
<td>50,000 IU</td>
<td>50,000 IU</td>
</tr>
<tr>
<td>Infant 6-11 months</td>
<td>100,000 IU</td>
<td>100,000 IU</td>
</tr>
<tr>
<td>Children 12 months plus</td>
<td>200,000 IU</td>
<td>200,000 IU</td>
</tr>
</tbody>
</table>

5.5 Meningitis

Epidemiology and Characteristics of the disease
Meningitis is an acute infection of the central nervous system usually caused by Neisseria meningitides,
Haemophilus influenzae, or streptococcus pneumoniae.

Epidemics of bacterial meningitis due to meningococcus (N. meningitides) are more likely to occur in sub-Saharan Africa, in an area known as the "African meningitis belt" (or "Lapeyssonnie’s belt"). Meningococcus is a gram-negative bacterium. Within this species, 12 serogroups have been identified A, B, C, D, X, Y, Z, W135, 29E, H, I, L. Serogroup A, is predominantly involved during epidemics. Type C is also involved although to a less extent.

Meningococcal meningitis was first recognized in Ethiopia in 1902. Outbreaks were reported in 1935, 1940, 1950, 1964, 1981 and 1989. The 1981 and 1989 outbreaks were the largest ever recorded in Ethiopia with 50,000 cases, 990 deaths in 1981, 45,806 cases, and 1686 deaths in 1989. The 1981 epidemic affected the northern and western parts of Ethiopia but that of 1989 affected all regions of the country.
Transmission: human to human via airborne droplet spread.

Determinants of the disease:
The following factors are thought to favor infection by meningococci:

- Increase virulence of the organism from groups, A, B and C and virulence of certain clones within a serogroup;
- Alteration of an individual’s nasopharyngeal mucosa because of climatic changes, such as cold, dry weather or seasonal winds or because of a viral infection;
- Immune deficiency;
- Overcrowding: transmission is increased when many people share the same enclosed living space, densely populated urban areas, and poor socio-economic conditions;
- Age 6 months to 30 years old people are at higher risk. The illness becomes far
less common in those over the age of 30, with 80 to 90 percent of cases occurring in those below this age.

Case definitions

**Suspected case:**
- Adults
  - A patient with abrupt onset of fever (> 38.5°C) with stiff neck or petechial rash
- Infants < 1 year old
  - Neck rigidity and fever may be missing. Patient must have in addition bulging fontanelle

**Probable case:**
- Suspected case + cloudy CSF + Gram negative diplococcus OR
- Suspected case with ongoing epidemic
Confirmed case:
- Suspected or probable case with latex agglutination or pastorex positive for N. meningitides. OR
- Positive culture of CSF or blood with identification of N. meningitides.

Threshold level for epidemic
- An epidemic of meningitis can be declared when 15 cases are reported per 100,000 inhabitants per week.
- If the population is less than 30,000, 5 cases in a week or doubling of the number of cases over a three week period (e.g. week one: 1 case, week two: 2 cases, week three: 4 cases). An increase in the number compared to the same time in previous years is also adequate to declare an epidemic of meningitis.
- In special situations involving group of people such as refugees or displaced persons call for immediate response,
including mass vaccination, when two cases of meningitis are confirmed, irrespective of the population size.

**Investigation**

- Confirm the clinical diagnosis of meningitis in the index case.
- Obtain CSF samples from as many patients as possible.
- Identify the causative organisms by gram stain of CSF, culture and latex agglutination test.
- If a meningococcus is incriminated as the cause of an outbreak:
  a) Determine its serogroup
  b) Determine its drug sensitivity.

**General management**

If criteria for epidemic threshold rates are met the following actions are necessary:

- Intensify active surveillance for the detection of cases.
- Initiate mass vaccination of the age groups at risks if causative organism belongs to serogroup A or C.
- Distribute treatment supplies to health facilities.
- Inform the public and limit movement of people.
- Mobilize community to permit early case detection and treatment, and improve vaccine coverage during mass vaccination campaigns for epidemic control.
- Minimize over crowding.

**Specific management**

- Assure rapid and appropriate treatment for cases with oily chloramphenicol/ treat according to the treatment protocol. If necessary establish temporary treatment centers.
Table 5.4. Standard treatment of meningitis in urban area:

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Dosage: Per kg Per 24 hrs.</th>
<th>Average Individual dose Route Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystalline penicillin</td>
<td>350,000 500,000</td>
<td>1-4 yrs 1 mega unit IV/IM 5-7 days</td>
</tr>
<tr>
<td>Crystalline penicillin</td>
<td>350,000 500,000</td>
<td>5-11 yrs 2 mega units IV/IM 5-7 days</td>
</tr>
<tr>
<td>Crystalline penicillin</td>
<td>350,000 500,000</td>
<td>&gt;12 yrs 3 mega units IV/IM 5-7 days</td>
</tr>
</tbody>
</table>

Note: In conditions where intravenous infusions are difficult to maintain, procaine penicillin G, 1 million units IM every 8 hours may be instituted after the third of IV penicillin treatment.
**Standard treatment for rural areas:**
Long acting chloramphenicol in oil (500mg/2ml)  
Presentation and route of administration: Vial (2ml) = 500mg for IM injection only.  
The preparation must never be given intravenously.  
The required dosage should be split in to two volumes, each half to be given at separate site.

<table>
<thead>
<tr>
<th>Age group</th>
<th>Dose in mg/gm</th>
<th>Dose in ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>6mos-1 year</td>
<td>500 mg</td>
<td>2ml</td>
</tr>
<tr>
<td>12-23 months</td>
<td>1.0 gm</td>
<td>4ml</td>
</tr>
<tr>
<td>2-5 years</td>
<td>1.5 gm</td>
<td>6ml (in 2 sites)</td>
</tr>
<tr>
<td>6-9 years</td>
<td>2.0 gm</td>
<td>8 ml (in 2 sites)</td>
</tr>
<tr>
<td>10-14 years</td>
<td>2.5 gm</td>
<td>10 ml (in 2 sites)</td>
</tr>
<tr>
<td>14 years +</td>
<td>3.0 gm</td>
<td>12 ml (in 2 sites)</td>
</tr>
</tbody>
</table>
Duration of therapy

- Usually a single dose is enough;
- If there is no improvement in the patients condition after 48 hours, repeat the same dose of oily chloramphenicol;
- If there is no improvement after a further 24 hours (and assuming the diagnosis is confirmed) begin treatment with ampicillin.

If there has been no improvement, re-assess the patient, and re-evaluate the initial diagnosis.

The use of chloramphenicol in oil suspension is not restricted to the rural areas but may be used in urban areas where personnel and IV equipment are limited. Oily chloramphenicol should be used for epidemic meningitis.

Infants: Ceftriaxone

Advantages:

- In infants other (Haemophilus Influenza, Streptococcus Pnuemoniae) are common even during the course of outbreak.
• No contraindication in pregnancy and lactating women.

Presentation:
Vials of 500 mg and 1 gm, IM and IV
Dosage: 80 mg/kg IM single dose per day for 5 days.

5.6 Relapsing Fever

Epidemiology and Characteristics of the disease
Relapsing Fever (RF) is an acute infection by spirochetes of the genus *Borrelia*. It is characterized by periods of fever lasting 2-9 days alternate with afebrile periods of 2-4 days; the number of relapses varies from 1 to 10 or more. The disease has two epidemiological varieties, louse-borne and tick-borne. Louse-borne RF runs a more severe clinical course than tick-borne RF. *Borrelia recurrentis* is the sole cause of louse-borne RF. The body louse is the only vector of louse-borne RF and human beings are the only known host. Louse-borne RF is endemic in central and East Africa. In Ethiopia it occurs mainly in
highland areas, especially during the cold rainy season.

**Transmission:** humans acquire infection when infected body lice are crushed and their fluids contaminate mucous membranes or breaks in the skin. Spirochetes are not transmitted directly by the bite of a louse or by inoculation of louse feces.

**Determinants:**
- Epidemics are common in wars, in famine or in other situations where malnourished, overcrowded populations with poor personal hygiene, such as in prisons.

**Case definition:**
**Suspected case:**
Any person presented with an abrupt onset of rigors with fever, usually remittent, head ache, arthragia and myalgia, dry cough, epistaxis.
Confirmed case:
A suspected case with demonstration of Borrelia in peripheral blood film.

Investigation
- Investigate the case to determine the risk factors contributing for the transmission.
- Investigate contacts and keep all immediate contacts under surveillance.
- Collect specimen for laboratory.

General management
- Report the index case to the next level.
- Search for additional cases in locality of confirmed cases.
- Interrupt the infection chain by delousing using 10% DDT or soaking or steaming clothing and bed sheets in boiling water.
- Conduct community education on personal and environmental hygiene.
Manual on Investigation and Management of Epidemic
Prone Diseases in Ethiopia

• Analyze the cases by time, place and person and take actions to improve the epidemic control activities.
• Establish regular reporting system.

Specific Management
Treat any individual suspected and confirmed cases with appropriate therapy in closely monitored setting.

Single dose of penicillin, is usually accompanied by less frequent and less severe reaction. However, some patients may fail to clear the spirochetes or experience a relapse. While single dose of Tetracycline is associated with more frequent and severe reaction, there is little treatment failure or few or no relapse.

The drug of choice is therefore,

1. Penicillin G, 400,000-600,000 unit IM, followed by oral Tetracycline 500 mg every 6 hours for 2 more days.
2. Erythromycin 500 mg as a single dose for pregnant mothers and children.
3. Close monitoring of fluid balance in cases of Jerish-Herxhemier reaction that may occur following antibiotics treatment.

5.7 Typhoid Fever

Epidemiology and Characteristics of the disease

Typhoid fever is a systemic bacterial disease characterized by insidious onset of fever, severe headache, malaise, anorexia. It is caused by Salmonella typhi; a gram negative, aerobic, rod like organism.

Human beings are the only reservoirs of infection. All ages and both sexes are susceptible. About 2-4% of typhoid patients become chronic carriers of the infection. Food handlers, especially if they are intermittent carriers are particularly dangerous and have been responsible for many epidemics.

Transmission: infection is acquired through ingestion of contaminated water and food by feces
and urine of patients and carriers. Flies may infect foods in which the organism multiplies to achieve an infective dose.

**Risk factors:**
- Areas without safe water supply
- Areas without good sanitation

**Case definition**

**Suspected case:**
Any person with gradual onset of remittent fever (rising in step ladder fashion) in the 1st week, headache, arthralgia, anorexia, constipation and abdominal pain.

**Confirmed case:**
- A suspected case with widal test, “O” titer of 1/160 and more is very suggestive.
- A suspected case with positive blood culture at the 1st week or positive stool culture at 3rd, 4th and 5th week of illness is very definitive.
Investigation

- Investigate the case to determine risk factors contributing to transmission.
- Obtain blood or stool specimen for confirming the epidemic.

General management

- Report the suspected case to the next higher level of the health system.
- Search for additional cases in the locality of confirmed cases.
- Strengthen case management and treatment.
- Mobilize community to enable rapid detection and treatment.
- Identify high-risk populations using person, place, time data.
- Reduce sporadic and epidemic-related cases by:
  - Promoting hand washing with soap or ash and water after defecating and before handling food,
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

- Strengthening access to safe water supply and storage, and
- Use of latrines and safe disposal of human waste.

Specific management
- Treat the suspected cases with antibiotics based on recent susceptibility results, if available.
- Chloramphenicol 500 mg four times a day for 14 days for adults is a drug of choice or Ciprofloxacin 500 mg oral twice a day for 5-7 days.
- Chloramphenicol 50-100mg/kg body weight for 14 days for children.
5.8 Epidemic (louse-borne) Typhus

Epidemiology and Characteristics of the disease
Typhus is a febrile disease caused by Rickettsia prowazeki and characterized by variable onset; often sudden and marked by headache, chills, prostration, fever and general pains. Pediculus humanus corporis (body and head louse), which is peculiar to humans, is the only important vector of epidemic typhus.

Cases of epidemic typhus now occur in significant numbers in Ethiopia and probably in highland areas of impoverished countries.

Transmission: Human beings generally are infected when rickettsia laden louse feces are rubbed into the broken skin, scratching the louse bite facilitates this process. Pathogenic rickettsias reside for a long period of time in patients with epidemic typhus.
Determinants:

- Overcrowding
- In colder areas where people may live under unhygienic conditions and are louse infested; enormous and explosive epidemics may occur during war and famine.

Case definition

Suspected case:
Any person with an abrupt onset of headache, chills and rapidly mounting fever, malaise, prostration and rash.

Confirmed case:
A suspected case with weil-felix reaction of the proteus strain OX-19 with four fold rise in titer, or a single titer equal to or greater than 320 in the second week of illnesses.
Investigation

- Investigate the case to determine the risk factors contributing for the transmission.
- Investigate of contacts and all immediate contacts should be kept under surveillance for 2 weeks.
- Collect specimen for laboratory confirmation.

General management

- Report the index case to the next level.
- Search for additional cases in locality of confirmed cases.
- Interrupt the infection chain by delousing.
- Conduct community education on personal and environmental hygiene.
- Analyze the cases by time, place and person and take actions to improve the epidemic control activities.
- Establish regular reporting system.
Specific management
Treat any individual suspected and confirmed cases with appropriate therapy in closely monitored setting.

Treatment of Typhus
1. Tetracycline 500mg PO QID for 7 to 10 days for adults except pregnant women or Chloramphenicol with same dose for adults including pregnant mothers.
2. Chloramphenicol 50-100mg/kg body weight for 7 to 10 days for children.
3. Doxycycline 200 mg in a single oral dose during heavy epidemics.

5.9 Visceral Leishmaniasis (Kala-azar)

Epidemiology and Characteristics of the disease
The leishmaniases and the suffering they cause are threatening 350 million men, women and children in 88 countries around the world; 12 million of these people are already affected by the disease which, in its worst form, is fatal. Visceral leishmaniasis is
distributed throughout the low lands of Ethiopia with varying degree of endemicity. The most important foci are the Metema and Humera low lands in the north-west, the Segen valley and its surroundings in Konso (South-west) and the lower Omo plains (South-west). The north eastern part of the country along the Awash valley to the Ethio-Djiboutic border is as well potentially endemic.

The leishmaniasis are parasitic diseases with a wide range of clinical symptoms: of mainly cutaneous, mucocutaneous and visceral. The leishmaniasis are caused by different species of protozoan parasites belonging to the genus leishmania.

Visceral leishmaniasis is characterized by irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anemia (occasionally serious). If left untreated, the fatality rate can be as high as 100%. In epidemic visceral leishmaniasis, people of all ages are susceptible except those who acquired
immunity during a previous epidemic. Males are affected more often than females in a ratio of 4:3.

**Transmission:** the disease is transmitted to humans by the bite of a tiny 2 to 3 millimeter-long insect vector, the phlebotomine sandfly.

**Risk factors:**
- Movement of non-immune people into potential visceral leishmaniasis endemic areas
- Malnutrition;
- Ecological change in favour of the sand fly vector.

**Case definition**

**Suspected case:** Any person with irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anemia.
Confirmed case:
A suspected case with demonstration of the parasite in stained smears from spleen, bone-marrow, lymph gland aspirates or blood.

Investigation
- Investigate the case to determine risk factors contributing to transmission.
- Perform serological test for suspected cases.
- Make/obtain confirmed parasitological diagnosis in stained smears from spleen, bone-marrow, lymph gland aspirates or blood.

General management
- Report the suspected case to the next higher level of the health system.
- Search for additional cases in locality of confirmed cases.
- Strengthen case management and treatment.
• Mobilize community to enable rapid detection and treatment.

• Identify high-risk populations using person, place, time data.

• Reduce sporadic and epidemic-related cases by:
  o Personal protection using insect repellants applied to the skin and insecticide-impregnated bed nets or curtains;
  o Spraying of residual insecticides inside and around house;
  o Clearing the sites (used for resting and breeding) of certain species of sand fly vectors.

**Specific management**

• Treat the confirmed cases with sodium stibogluconate or other available effective alternative drugs.
5.10 Yellow fever

Epidemiology and Characteristics of the disease
Yellow fever is viral hemorrhagic disease caused by a flavivirus. Large scale epidemics occur every 3 to 10 years in villages or cities worldwide. Sporadic cases can occur regularly in endemic areas. The incubation period is 3 to 6 days after the bite from an infected mosquito. While only the minority of cases are severe, case fatality rate may be 25% to 50% among patients with syndrome of hemorrhage, jaundice, and renal disease.

Transmission: transmitted human-to-human via the bite of aedes mosquitoes (urban epidemic) or via forest mosquito species and forest primate reservoir (jungle cycle).

Determinants:
- Sporadic cases often linked to occupation or village location near woods or where monkeys are numerous.
Case definition

Suspected case:
A person with acute onset of fever followed by jaundice within two weeks of onset of first symptoms. Hemorrhagic manifestations and renal failure may occur.

Confirmed case:
A suspected case with laboratory confirmation (positive IgM and viral isolation) or epidemiologic link to confirmed cases or epidemics.

Investigation

- Collect specimen for laboratory confirmation
- Investigate the case to determine how transmission occurred.
- Plan for an immunization activity.
General management

- Report case-based information immediately to the next level.
- Mobilize community early to enable rapid case detection and treatment.
- Conduct a mass campaign in appropriate age group in the area (ages 6 months and older) and in areas with low vaccine coverage.
- Identify high risk population groups and take steps to reduce exposure to mosquitoes. Improve routine and mass vaccination campaigns to include yellow fever in high risk areas.

Specific management

- Treat and manage the patient with supportive care administered under a bed net (ORS for rehydration, paracetamol for fever) and strict isolation procedures.
5.11 Avian Human Influenza (AHI)

AI is an infectious disease caused by influenza type A virus which occurs naturally in all birds, especially wild water birds (e.g. ducks). Birds carrying the virus spread it through saliva, nasal secretions and feces. Today, there is no vaccine for preventing the infection and also it is unclear that if antiviral medications that are commonly used for influenza are effective.

Definition:
Avian Influenza /fowl plague/ bird flu / is a zoonotic viral disease that affect chickens, turkeys, other wild birds and human being.

Types of AI
1. Low pathogenic AI (LPAI)
   - Most common influenza infection in birds
   - Causes mild and in-apparent infections
   - May be any subtype
2. Highly pathogenic AI (HPAI)
   - Some H5 or H7 subtypes
   - Causes severe illness in poultry and often death
   - LPAI H5 or H7 subtypes can mutate into HPAI H5 or H7 subtypes
   - Current H5N1 is the common type

**Epidemiology and characteristics of disease**

An epidemic of the disease was reported since 1510 and there were 4 pandemics in the 19th Century and 3 in the 20th century. The past experience indicates that there is no regularity to pandemics and no reliable basis for predicting when/where that might arise. The most recent cause for concern occurred in December 2003 that confirmed the cause of pandemic was H5N1 (type of virus with high pathogenic characteristics) avian influenza virus in human (Vietnam).

In Ethiopia, the influenza epidemic known as the ‘Hedar Basheta’ and also there were two distinct epidemic waves in 1918.
Since the current epidemic of 2003:-

- 50 countries have reported an outbreak in their Animals
- Efforts to control the outbreak (culling or death of > 150 million chickens occurred worldwide, economic loss > $12 billion in the Asian poultry)
- As no virus of the H5 sub-type has ever circulated widely in humans, vulnerability to infection with a pandemic H5 strain will be universal
- Pandemic threat might persist (months, years)

Hence, Avian and Human Influenza:-

- Impossible to predict
  - When the pandemic might occur
  - How severe its consequences might be.
- Recent vast increase in communication across world through
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

air passenger transport, land based communication and the opening of tourism will hasten the spread of pandemic influenza in few weeks.

Transmission:
The way of spread to Human:-

- Touching an infected bird, fluids or surfaces contaminated with fluids from infected birds
- Close contact with live or improperly cooked poultry
- Exposure during slaughter and preparation of domestic poultry for cooking
- Contact with dead wild birds or their parts
- Wild bird migration
- Animal and human populations in close proximity (farm animals and pets in/under/next to houses, live
animal markets (many species from many countries)

- Poor agricultural practices (inadequate infection control on farms, poultry excrement used in agriculture e.g., fed to pigs)

Determinants of infection:

- Within 7-10 days before symptoms begin:
  - Close contact with live, sick, or dead birds
  - In setting with confined birds
  - Contact with contaminated surfaces or environments
  - Ingestion of uncooked infectious poultry
  - Travel or residence in area affected by avian influenza outbreaks in animals...etc

- Uncertain risk of person to person spread:
Face to face contact
Touching or within 1 meter of suspected or diagnosed H5N1 patient without proper precautions
Touching or being within 1 meter of a person who has severe pneumonia or dies from an acute respiratory illness without proper precautions…etc

Case Definition
Community case:
- Sudden onset of Fever,
  • Cough,
  • sore throat and/or shortness of breath
  and
  - Have been in contact during the 7 days prior to the onset of symptoms with birds, including chickens, that have died of an illness or persons presenting with the above symptoms
Suspect/Probable case:

- Fever (>38°C)

and

One or more of the following symptoms:

- Cough;
- sore throat;
- shortness of breath
- diarrhea, vomiting, bleeding, conjunctivitis, abdominal pain and pleurisy

and one or more of the following:

- Laboratory evidence for influenza A by a test that does not sub-type the virus.
- Having been in contact during the 7 days prior to the onset of symptoms with a confirmed case of Influenza A/H5 while this case was infectious.

- Having been in contact during the 7 days prior to the onset of symptoms with birds, including chickens, that have died of an illness or presenting with the above symptoms.
• Have worked in a laboratory during the 7 days prior to the onset of symptoms where there is processing of samples from persons or animals that are suspected of having highly pathogenic avian influenza (HPAI) infection.

OR

Death from an unexplained acute respiratory illness

AND

Residing in area or travel to an area where HPAI is suspected or confirmed

Probable case:
  • Fever (temperature > 38°C)

AND one or more of the following symptoms:
  • cough; sore throat; shortness of breath
AND

• limited laboratory evidence for Influenza A/H5 (H5 specific antibodies detected in a single serum specimen)

Confirmed case:
An individual for whom laboratory testing demonstrates one or more of the following

• Positive viral culture for Influenza A/H5
• Positive PCR for Influenza A/H5
• Positive Immunofluorescence antibody (IFA) test
• 4-fold rise in Influenza A/H5 specific antibody titer in paired serum samples

Investigation

• Identification of a single case is considered an epidemic
• Immediately reportable disease -24 hr
• Reported - case based reporting format.
• Recommended specimen should be collected timely, properly stored and transported.
• Zero reporting/week should be initiated and instituted
• Usually the investigation procedure will have three phases:

a. Pre-Investigation
  • Planning the Response

b. Investigation
  • Case Definition
  • Specimen Collection
  • Case Finding
  • Interviewing
  • Contact Identification
  • Reporting
  • Data Management
  • Creating an Epidemic Curve
  • Assessing Transmission
  • Writing a Summary Report

c. After the Investigation
  • Evaluate Performance
Epidemic management

- manage cases effectively to prevent complications
- identify cause of the outbreak
- inform the general public about the outbreak and outbreak response
- strengthen and continue the routine surveillance - both active and passive
CHAPTER SIX
MANAGEMENT OF
OUTBREAKS IN SPECIAL SETTINGS

6.1. Epidemic in school settings
Dealing with epidemic outbreaks is one of the difficult challenges facing school health. Though the general principles of epidemic investigation and control hold also true for outbreaks in schools or campuses, there are some points that deserve especial consideration and further discussion.

In school settings, apparent outbreaks of disease of unknown cause, possibly school related such as diarrhoea, rash or fainting or outbreaks of possible exposure to communicable disease (measles, TB, meningococcal disease, hepatitis A in a food handler, typhoid etc) can occur.
Helpful Principles for outbreak investigation and management of such illnesses in school settings include:

6.1.1 The schools health unit should be alert of epidemic possibilities
Any disease in which the occurrence is unusual over a given time period - such as two or more cases of hepatitis, salmonella, etc - should be reported to the local body responsible for initiating investigation and control measures. An unexpectedly high absentee rate with symptoms such as diarrhoea, fainting, rash, illness, or vomiting should alert school personnel to the existence of possible outbreaks in school. The speeds with which disease occurrences need to be reported are very much dependent on the incidence/prevalence of the disease and the action that needs to be taken to address it.

6.1.2 Start investigation as early as possible
During an outbreak in school and possible exposure in school, an investigation should be started
immediately. The school health team and representatives from administration should contact the Public Health Authority of the locality in order to control the epidemic. An investigation should be started to determine the cause and measures to contain the epidemic and prevent a reoccurrence should be taken.

An investigation involves gathering lots of information as quickly as possible. Information gathered will come from laboratory testing of specimens, interviewing both those who are cases and those who are not cases and from onsite assessments of the environment.

Methods of investigation include: verifying diagnosis, establishing the existence of an outbreak where the cases observed are greater than expected; characterizing outbreaks such as defining cases describing pupil (including grade level, etc), places (including class rooms, blocks, seats, residence, etc ) and time; identifying potential sources of agents modes of transmission; identifying populations at risk
and developing and testing hypotheses regarding the source of transmission and initiating case control studies, environmental cultures, or the testing of suspect sources. Control measures to eliminate or reduce the spread of the illness should be implemented at once for example administering preventive therapy such as vaccination, measures targeted at water and food supplies in the school.

6.1.3 **Surveillance should be maintained for new cases**
Continuous and systematic collection and reporting of cases of communicable diseases not only during epidemic periods but also at all other times is a strong means of detecting and controlling epidemics of communicable diseases in school settings as well as evaluating disease control measures in schools. In school settings, reportable cases include those of selected preventable disease - measles, mumps, TB, meningococcal disease, hepatitis A, and chicken pox. However, it is recommended that infectious disease surveillance in school children should be part of
national communicable disease surveillance system. In conducting active surveillance, involving students like class representatives is proven effective in epidemic preparedness and management.

6.1.4 Effective communication can't be overemphasized

In addition to the real concerns about the spread of disease, there will often be problems of communication, relationships with administration, faculty, parents, other physicians in school, as well as dealing with public hysteria engendered by the media and the community.

The outbreak should be discussed thoroughly with experts from the Health Department of the local government, and the public should be reassured. Forming an ad hoc committee composed of parents to monitor and discuss evaluation of the procedures is important in order to make sure that procedures are carefully followed and if mistakes have been made, performance can be improved. In this manner, school outbreaks can be dealt with efficiently.
6.1.5 Learn from the epidemic to prevent occurrence of similar future epidemics

Once an outbreak is controlled, it is important that the lesson learned from the investigation is used to identify measures that can be put in place to reduce or eliminate the likelihood of a similar outbreak in the future. This may involve things such as policy and procedure changes, ongoing education programs, environmental changes, etc.

6.2 Epidemic in Prison settings

6.2.1 Prisons and prisoners: introduction

The term ‘prison’ is used to mean any place of detention. The term therefore includes pre-trial or remand centers, labour colonies, reformatories, prisoners of war camps, immigration centers, police stations and other sites where people are deprived of their liberty.

Prisoners usually return to society after serving their sentence, or earlier because of pardons or amnesties. However, there is often little collaboration between detaining authorities and the civilian sectors
responsible for health care delivery or social welfare; this remains a serious challenge in prison health. In addition to a weak collaboration, another problem is the steady rise in prison populations throughout the world despite efforts for penal reform and the use of alternative punishment systems. It is estimated that on any given day, the number of people in prison in the world is 8 to 10 million. As many are detained for short periods and the rates of admissions and releases are almost equivalent, the actual numbers passing through prisons each year is potentially 4-6 times higher than the earlier figure. Prisoner populations are composed predominantly of men aged 15-44 years. There is usually an over-representation of marginalized groups within the civilian community, such as ethnic minorities, illegal immigrants, substance abusers, the mentally ill and the poor.

Living conditions inside prisons are often appalling. In any country where resources are scarce, those considered ‘criminals’ may become the lowest priority
for funds. Prisoners are often housed in overcrowded facilities with inadequate ventilation, hygiene and sanitation. Food that is provided can be unappealing and nutritionally inadequate.

Health services may be weak or absent. Illegal behavior such as the use of alcohol, drugs or sexual activities (with or without consent) may continue unchecked. Such conditions are ripe for the outbreak of epidemic diseases, particularly communicable diseases including TB and HIV.

6.2.2 Prisons and communicable disease epidemics

Prisons can act as breeding grounds for communicable diseases, and can introduce new, unhealthy practices (drug use, unsafe sex). People often enter prison with less healthy lifestyles than the general population, having been more likely to abuse alcohol, tobacco and illegal drugs, more likely to suffer mental disorder and at increased risk of communicable diseases. Vigorous health promotion programs can improve the lifestyles of both prisoners
and prison staff, and may also improve their productivity and morale.

Prisoners are members of the general population: they come from and usually return to the community. The relationship between the health of prisoners, their families and the wider community is thus an important concern. Limiting the spread of communicable diseases in prison benefits both prisoners and the wider community.

In general, reducing the rate of incarceration through penal reform is fundamental to improving prison health. By decreasing overcrowding, transmission of infectious disease can be reduced, and living conditions can be substantially improved. In addition, fewer prisoners can mean greater resources to improve prison conditions both for prisoners and staff. But, specifically there are recommended actions for the common epidemic prone diseases in prison settings.
6.2.3 Epidemics of Tuberculosis in prisons

6.2.3.1 Why is Tuberculosis an epidemic prone disease in prison settings?

TB is reported to be up to 100 times more common in prisons than in the civilian population. The reason why Tuberculosis is among the epidemic prone diseases in prison settings is that a collection of risk factors for development and spread of the disease co-exist in prisons. This concentration of risk factors can ignite TB epidemics that are not restricted to the confines of a prison. These factors include:

1. A disproportionate number of prisoners are derived from population groups already at high risk of TB infection and disease (e.g. those addicted to alcohol or illicit drugs, the homeless, the mentally ill, former prisoners), who often do not have access to adequate treatment in civilian life.

2. Prisons promote transmission of TB infection through prolonged and repeated exposure to Mycobacterium tuberculosis as a result of: late case detection, and the lack of respiratory isolation and
inadequate treatment of infectious cases, high turnover of prisoners through repeated transfers within the prison system, release and recidivism, overcrowding, poor ventilation, etc.

3. Prisoners are also at risk of rapid progression to TB disease following recent infection or reactivation of latent infection through: co-existing pathology, particularly HIV and intravenous drug use, poor nutritional status and physical/emotional stresses.

If TB in prisons is to be controlled effectively, all of these factors must be acknowledged and addressed wherever possible.

The rate of Multi Drug Resistant Tuberculosis (MDR-TB) is also more common in prison settings as factors that encourage transmission of regular TB will enhance the spread of Multi Drug Resistant TB. In addition, various prison aspects may particularly enhance the development of MDR-TB. These include: fewer resources and weaker health care provision than for the society in general, leading to
erratic drug supplies and inadequate treatment, failure to complete supervised treatment courses through repeated inter prison transfer where treatment completion is not assured, release during treatment when TB services are not accessible, hidden defaulting through coercion by other prisoners or a desire to remain a ‘TB patient’ and receive better living conditions, etc.
These factors must be addressed as a priority to prevent the development of epidemic drug-resistant TB.

6.2.3.2 Methods of Tuberculosis Epidemic Control in Prison settings
a. Early diagnosis and Treatment of TB cases in prisons
The risk of transmission of TB infection depends on the concentration of infectious droplets in the air and the duration of exposure. The greatest risk of TB epidemic in prisons is therefore when a case of TB in prison remains undiagnosed or ineffectively treated. Hence, the most effective way to reduce transmission
of TB is the early diagnosis and effective treatment of infectious TB cases.

Many of the factors which promote TB transmission can be remedied by simple and inexpensive administrative measures to obtain early identification of cases and prompt initiation of effective treatment of infectious cases.

Early diagnosis of potentially infectious TB patients is possible, for instance, by screening at entry, effective case-finding through self-referral, use of cough registers, training and education program for staff and visitors, effective procedures and timely communication between laboratory and health personnel, etc.

Effective treatment of infectious TB cases is possible by rigorous direct observation of treatment (DOT) and smear monitoring until the completion of treatment.
b. Isolation of prisoners with infectious tuberculosis

It is standard infection control practice in hospitals for patients with infectious TB to be separated from other patients until treatment has rendered them non-infectious. In most cases this takes about two weeks from the start of effective treatment. Similarly, prisoners suffering from infectious TB should be housed separately from other prisoners until they are non-infectious. Where MDR-TB is not common, this should be after a minimum of two weeks directly observed treatment and clinical improvement. Where MDR-TB is common, at least one negative smear is also required.

Separate housing does not necessarily mean an entirely separate facility. However, a separate building or room should be allocated for infectious cases if at all possible. Care should be taken to avoid contact between infectious cases and other prisoners in bathing, dining or recreational rooms and punishment cells. If a centralized treatment facility is used, it is recommended to create separate
departments (preferably units with non-shared air/ventilation) for patients: being assessed for TB disease (diagnostic unit), with smear-positive TB, with smear-negative pulmonary and extra pulmonary TB and those who have become smear-negative through treatment (if they are not to be transferred back to their prisons of origin), who refuse or default from treatment and with chronic TB.

This separation is useful for operational reasons where there are large numbers of patients and may reduce the risk of re-infection or super-infection. Where multi drug resistant disease is common, separation of infectious cases from other prisoners is extremely important because of the difficulties and expense of treating these forms. Separate housing should be maintained at least until smear negativity is confirmed.

Family visits should not be restricted because of a diagnosis of infectious TB, but precautions should be
taken to limit transmission of infection (e.g. ensure meetings take place in well ventilated areas).

c. Improving ventilation in prisons

Most simply, involves maximizing natural ventilation and controlling the direction of airflow by opening windows or external doors at opposite ends of a room and using fans. Other more complex and costly methods include: Mechanical ventilation (air extraction fans, exhaust ventilation systems, air filtration or ultraviolet germicidal radiation, etc. Other methods must be maintained in a good state of repair and installed with expert guidance and if used, should be prioritized to the highest risk areas (e.g. sputum collection rooms, laboratories, autopsy suites).

d. Encouraging personal respiratory protections in prisons

Personal respiratory protections include wearing surgical masks. Surgical masks are not designed to protect the wearer. However, infectious TB patients
may wear surgical masks to protect others during transport or meeting visitors for example. However, care should be taken not to stigmatize. TB patients, and health education and information should accompany the distribution of masks.

**e. Evaluation of epidemic control measures**

Evaluation of implementation of infection control measures (e.g. proportion of new entrants screened for TB; time between suspicion of TB and request for sputum analysis, time from collection of sputum to receipt of results, time from receipt of positive result to initiation of treatment).

**f. Other measures**

Prophylactic treatment must be considered for infants born to mothers with active TB (isoniazid 5-10mg/kg per day for 6 months). These infants should subsequently be vaccinated with BCG. TB treatment of the mother does not preclude breast-feeding and where possible breast-feeding should continue.
BCG vaccination acts by preventing the spread of TB bacilli in the body after initial infection rather than reducing the risk of infection. It has only been consistently demonstrated to reduce the risk of progression from infection to disseminated disease in children, while its protective role in adults is unclear. BCG should, however, be given to all children born in prison, as soon as possible, according to the Expanded Programme of Immunization (EPI) schedule. Children under 5 who enter prison to live with their parents should be vaccinated with BCG, if there are no contraindications and they did not receive the vaccination as an infant.

6.2.4 Epidemics of HIV in prisons

6.2.4.1 Why is HIV an epidemic prone disease in prison settings?

Rates of HIV in detained populations are thought to be up to 75-fold than in civilian populations. This is because, like for Tuberculosis, prisons present a high concentration of risk factors for the transmission of
HIV infection. These include the facts that: a disproportionate number of inmates come from, and return to, backgrounds where the prevalence of HIV infection is high, risk behaviors such as intravenous drug use and unsafe sexual practices (with or without consent) commonly occur in prisons, risk behaviors and HIV may not be officially acknowledged so hindering efforts at education regarding safer practices, interventions to reduce risk of HIV infection (such as the provision of clean injecting equipment or condoms) may be restricted or considered unacceptable, there may be a high frequency of tattooing using unsterilized equipment, presence of other sexually transmitted diseases (e.g. syphilis) in prisons, etc.
6.2.4.2 Methods of HIV Epidemic Control in Prison settings

a. Health education
Education programs for all staff and inmates on HIV and other blood borne disease – routes of transmission, risk behaviors, risk reduction are vital.

b. Practice of Universal precaution
The use of universal precautions (treating blood or bodily fluids from all individuals as if they contain infectious pathogens)- the use of gloves for injections, the use of sterile disposable needles for injections (or if needles must be reused ensuring that they are designed to be re-used and are completely sterilized through autoclaving before each use), care in the use of needles and sharp equipment to avoid injury, the use of special puncture proof containers for the safe disposal of used needles and incineration so that they are not diverted for illicit drug use.
c. Providing medically supervised narcotic detoxification programs (e.g. narcotic substitution) for addicts.

d. Making condoms freely and confidentially available.

6.2.5 Epidemic of other health problems in prisons
Prisons also present other communicable disease risks to staff and inmates. These include transmission of blood-borne or sexually transmitted infection (e.g. hepatitis, syphilis, gonorrhoea), food or water borne diseases and vector borne diseases such as epidemic typhus and relapsing fever. Many can be avoided by scrupulous attention to hygiene and safe working practice. This includes frequent hand washing, a safe water supply and sewage disposal, kitchen hygiene and control of infestations. Besides, it is also vital to screen, diagnose, treat and follow-up the course of disease progression.
6.3 Epidemics in hospital settings: Epidemic of nosocomial infections

Hospital-acquired infections (Nosocomial Infections) can be defined as those that were neither present nor incubating at the time the patient was admitted. However, the symptoms might occur after the patient is discharged from the hospital. For example, for surgical site infection, as many as 70% of infections may present after discharge. Nosocomial infections continue to be a major cause of morbidity and mortality. These infections prolong hospital length of stay, increase mortality, and raise the overall cost of healthcare.

Principles:

6.3.1 Early notification
The Infection Control Unit of the hospital should be notified about clusters of nosocomial infection, resistant and or epidemiologically important organisms or communicable diseases in patients, staff, or visitors. In some instances, one case of an
infection may require a response, in other diseases clusters or an increases in occurrence.

6.3.2 Follow the following procedures

1. Verify diagnosis of identified patients;
2. Confirm existence of an outbreak;
3. Institute initial control measures (proper isolation);
4. Develop a working case definition;
5. Direct nursing units to identify patients who have been exposed during an outbreak;
6. Find cases (by interview, chart review and microbiologic surveillance, as indicated);
7. Evaluate previous hospital experiences with the organism or disease; list (line) cases;
8. Create epidemic curve;
9. Develop a presumptive hypothesis on which to initiate additional reasonable control measures;
10. Recommend prevention and control measures;
11. Provide education about the causative organism or epidemiology; and
12. Determine if any changes are needed in policy/procedures.
13. Evaluate the efficiency of the control measures.

6.3.3 Consult experts in the suspected infectious disease
Physicians with expertise in the suspected disease process or organism may be consulted when a disease with potential mass exposure is identified in a patient or staff member or when the potential exposure to other patients and staff members is beyond that which would normally be addressed by routine infection control.
6.3.4- Put nosocomial infection surveillance in place

If not yet in place, the occurrence of one epidemic is a good opportunity to commence surveillance of nosocomial infections in hospital settings so that future similar outbreaks can be prevented. Hospital programmes of infection control (IC) should include surveillance to detect common source outbreaks, identify problem areas, help set priorities for infection control activity, and meet national standards. Surveillance can also provide data to help convince clinicians and managers of the need for improvements in infection control practices. Surveillance must be performed in a systematic way with the aim of reducing rates of hospital infection. Surveillance results should be fed back to clinical and managerial staff and should lead to action.

The purpose of Nosocomial Infection Surveillance is to:

a) detect and monitor adverse events,

b) assess risk and protective factors,
c) evaluate preventive interventions, and
d) provide information to event reporters and
stakeholders and partner with them to implement
effective prevention strategies.

A well planned surveillance followed by action for
improvement can have a significant impact on rates
of hospital acquired infections (nosocomial
infections). Before beginning surveillance activities it
is essential to develop a clear plan. It should
address:

1) What questions are being asked,
2) How infections are to be defined,
3) How the data are to be collected, stored,
   retrieved, summarised and interpreted,
4) How to feed the results back to frontline
   practitioners, and
5) How to use the information to bring about
   change.

Surveillance practices are similar to clinical audit,
except that for an audit the practice and outcomes of
medical care (in this case the prevention and control
of HAI) is compared with a standard. By repeated audit cycles, practice is brought closer to the ideal.

It is often more meaningful and more useful to use surveillance data from a single institution to measure trends over time, either to alert staff to increasing problems or to monitor the effectiveness of interventions.

Formal surveillance of infections requires each patient to be assessed, often repeatedly, by trained staff. For this reason, true infection surveillance (and especially incidence surveillance) is very expensive due to the need for staff time. Because of this, surveillance is often done routinely by analysing laboratory reports, or by informal ward visits, or by a combination of the two.

However, it must be recognised that these methods are not accurate. Laboratory reports are not always indicative of true infection. Negative reports (or no report) do not always mean infection is absent.
Minimal Requirements for Nosocomial Infection Surveillance

i- Monitor infection patterns (sites, pathogens, risk factors, location within the facility)

ii- Detect changes in the patterns that may indicate an infection problem

iii- Direct the rapid implementation of control measures

iv- Monitor antibiotic use and resistance

Provide the staff with exactly the information they need in order to improve infection prevention practices.

6.4 Epidemics associated with disasters

Disasters are emergencies of a severity and magnitude resulting in deaths, injuries, illnesses and/or property damage that cannot be effectively managed by the application of routine procedures or resources. These events are caused by nature, the result of technological or manmade error, or from emerging diseases.
The common epidemic diseases associated with disasters are enteric diseases (cholera or typhoid), vector borne diseases (malaria, lose borne typhus and relapsing fever) or diseases due to close human contact (measles, meningitis etc…).

Epidemics following disaster are caused by population movements; which may lead to overcrowding when displaced persons move into areas in which physical structures have been damaged by the disaster. Overcrowding often causes a decrease in sanitation, with contamination of water or food supplies and a decline in nutritional status. Another cause of epidemics may be environmental change that favors breeding of vectors.

**Health intervention during disaster**

Health activities during disaster include developing health action plans and taking appropriate interventions during.
Health action plan

Disasters are often associated with health problems as the susceptibility of people to diseases increases with deprivation of basic necessities such as food and shelter. Every time a disaster is anticipated, a health plan should be prepared at any level of the health system. The plan should include the following tasks:

- Health and nutritional surveillance of the affected areas.
- Mass immunization of vulnerable population in the event of likely outbreak of epidemics, particularly against measles and meningitis.
- Regular and periodic disinfection of sources of drinking water.
- Medical examinations of children in schools and supplementary vitamins e.g. vitamin A.
- Early detection of malnutrition.
- Activities concerning the establishment and utilization of therapeutic feeding centers.
- Coordination of all stakeholders with respect to health measures.
• Provision of basic sanitation services.
• Timely procurement of commonly used medicines and sanitation materials.

Management of acute illnesses
In epidemics, local health services will have the responsibility for diagnosis and treatment of the increasing number of cases during the initial phases. The local availability of trained health personnel, basic diagnostic facilities and essential drugs and vaccines are essential for fighting outbreaks and reducing the mortality rate. Furthermore, it is important to have pre-established and readily available standardized treatment protocols and procedures which are well known to the health personnel.

Epidemic Control activities
In the long term, control of epidemics associated with disaster depends on a healthy environment (clean water, adequate sanitation, vector control, and adequate shelter), immunization, and the training of
health workers in early diagnosis and treatment. In principle, the three main methods of control are dealing with the source of infection; interrupting transmission; and protecting susceptible individuals (see the details on chapter two).
REFERENCES


Gaynes RP. Surveillance of nosocomial infections. In, Bennett JV, Brachman PS (eds) Hospital


Mike Ryan, Operational Aspects of Outbreak Investigation, World Health Organisation, Geneva


Ministry of Health, Department of Disease Prevention and Control. Guidelines for the prevention and
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia


WHO. Tuberculosis Control in prisons. A manual for program managers. CDS/TB/2001.281
## Annexes

### Annex 1. Outline for preparing epidemic preparedness and response plan of epidemic prone diseases

<table>
<thead>
<tr>
<th>Part I- The organism and disease</th>
<th>Part II- Prevention and Control</th>
<th>Part III- Epidemic Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Description about the nature and magnitude of the problem</td>
<td>List of prevention and control strategies of control, prevention and elimination phase of the disease epidemic/outbreak</td>
<td>3.1. Management</td>
</tr>
<tr>
<td>1.2 Description about causative organism</td>
<td>3.2. Method of Detection</td>
<td></td>
</tr>
<tr>
<td>1.3 The pathogenesis and clinical</td>
<td>3.3. Means of confirmation</td>
<td></td>
</tr>
</tbody>
</table>
problems - including case definition

1.4 Mood of Transmission and immunity

1.5 Treatment - including method of diagnosis, clinical assessment, management based on severity and classification of the diseases

3.4 Planning for a response, defining and agreement on planned response, management of response, method of provision of public information and list of post-outbreak activities
Anex 2. Treatment of diarrhea

Steps in diarrhea management:
1. Assess for dehydration
2. Rehydrate the patient
3. Antibiotics for cholera and dysentery
4. Feed the patient
5. Teach the patient and family

Assess degree of dehydration (DHN)

<table>
<thead>
<tr>
<th>Assessment of the diarrhea patient for dehydration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. LOOK AT CONDITION</strong></td>
</tr>
<tr>
<td>EYES THIRST</td>
</tr>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>Restless, Irritable</td>
</tr>
<tr>
<td>Sunken</td>
</tr>
<tr>
<td>Thirsty, drinks eagerly</td>
</tr>
</tbody>
</table>

Assessment of the diarrhea patient for dehydration

1. **LOOK AT CONDITION**
   - EYES THIRST
   - Well, alert
   - Normal

2. **FEEL SKIN**
   - Goes back
   - Drinks poorly or not able to drink
### DECIDE

#### PINCH quickly slowly very slowly

<table>
<thead>
<tr>
<th>PINCH</th>
<th>quickly</th>
<th>slowly</th>
<th>very slowly</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. DECIDE</td>
<td>The patient has no sign of DHN</td>
<td>If the patient has two or more signs of the above signs, there is some DHN</td>
<td>If the patient has two or more signs of the above signs, there is severe DHN</td>
</tr>
</tbody>
</table>

a. Rehydration of patient with severe DHN – treatment Plan C

- Start IV fluid immediately
  - Ringers lactate is best
  - Also give ORS if patient can drink, about 5ml/kg/hr
- Monitor very frequently
- Completely reassess adults after 3 hours and infants after 6 hours.
Ringer's lactate IV

<table>
<thead>
<tr>
<th>Age</th>
<th>First give 30 ml/kg in</th>
<th>Then give 70 ml/kg in</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (&lt; 12 months)</td>
<td>1 hour</td>
<td>5 hours</td>
</tr>
<tr>
<td>1 year and over</td>
<td>30 minutes</td>
<td>2.5 hours</td>
</tr>
</tbody>
</table>

b. Rehydration of patient with some DHN using ORS – treatment Plan B

<table>
<thead>
<tr>
<th>Age</th>
<th>&lt; 4 Months</th>
<th>4-11 Months</th>
<th>12-23 Months</th>
<th>2-4 years</th>
<th>5-14 years</th>
<th>15 years and over</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight in kg</td>
<td>&lt; 5</td>
<td>5-7.9</td>
<td>8-10.9</td>
<td>11-15.9</td>
<td>16-29.9</td>
<td>30 and over</td>
</tr>
<tr>
<td>ml</td>
<td>200-400</td>
<td>400-600</td>
<td>600-800</td>
<td>800-1200</td>
<td>1200-2200</td>
<td>2200-4000</td>
</tr>
</tbody>
</table>

This table shows the approximate amount of ORS solution to give in the first 4 hours to patients with some DHN. Use the age only when the patient's weight is not known.
If the weight is known, calculate the amount of ORS by multiplying the patient’s weight in kg by 75.

c. ORS for patient with No DHN – treatment Plan

A

<table>
<thead>
<tr>
<th>Age</th>
<th>Amount of ORS after each loose stool</th>
<th>Give enough ORS packets for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 24 months</td>
<td>50 – 100 ml</td>
<td>500 ml/day</td>
</tr>
<tr>
<td>2-9 years</td>
<td>100 – 200 ml</td>
<td>1 liter / day</td>
</tr>
<tr>
<td>10 years and over</td>
<td>As much as wanted</td>
<td>2 liters / day</td>
</tr>
</tbody>
</table>

Patients who showed no signs of dehydration when they were first assessed or patients who improved from dehydration and showed no dehydration may be treated at home.
Annex 3. Malaria treatment

a) First-line treatment
The first-line treatment of *P. falciparum* is artemether-lumefantrine administered for 3 days. For infants less than three months or five kg of body weight and pregnant women in the first trimester, oral quinine administered 3 times a day for 7 days.

**Artemether-lumefantrine**: Tablet containing 20 mg Arthemeter plus 120 mg Lumefantrine in a fixed dose combination.

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Age (years)</th>
<th>Number of tablets per dose twice daily for 3 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Day 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Morning</td>
</tr>
<tr>
<td>5-14</td>
<td>3mo - 2 years</td>
<td>1</td>
</tr>
<tr>
<td>15-24</td>
<td>3-7 years</td>
<td>2</td>
</tr>
<tr>
<td>25-34</td>
<td>8-10 years</td>
<td>3</td>
</tr>
</tbody>
</table>
b) Second-line treatment

If a P. falciparum positive patient returns back to facility with fever or history of fever between the 4th day and 14th day after treatment with Artemether-Lumefantrine, do blood examination for malaria parasites. In addition, ask the patient if he/she has vomited the drug or had diarrhea after treatment. Check also whether the drug taken is of reliable brand and is not expired. If the blood film is positive for asexual malaria parasites and other conditions are excluded, administer oral quinine if condition of the patient permits.
**Quinine 8 mg base/kg 3 times daily for 7 days**

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Age (years)</th>
<th>Oral (tablets) dosage to be given daily</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>200 mg salt</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300 mg salt</td>
</tr>
<tr>
<td>4-6</td>
<td>2-4 months</td>
<td>1/4</td>
</tr>
<tr>
<td>6-10</td>
<td>4-12 months</td>
<td>1/3</td>
</tr>
<tr>
<td>10-12</td>
<td>1-2 years</td>
<td>1/2</td>
</tr>
<tr>
<td>12-14</td>
<td>2-3 years</td>
<td>3/4</td>
</tr>
<tr>
<td>14-19</td>
<td>3-5 years</td>
<td>3/4</td>
</tr>
<tr>
<td>20-24</td>
<td>5-7 years</td>
<td>1</td>
</tr>
<tr>
<td>25-35</td>
<td>8-10 years</td>
<td>1 1/2</td>
</tr>
<tr>
<td>36-50</td>
<td>11-13 years</td>
<td>2</td>
</tr>
<tr>
<td>50+</td>
<td>14+</td>
<td>3</td>
</tr>
</tbody>
</table>

Quinine dosage for severe falciparum malaria:

**Whenever IV administration of quinine is not possible:**

1. Quinine 20 mg salt per kg loading dose IM in 2 divided doses, anterior thigh.
2. Then quinine 10 mg salt per kg IM every 8 hours until patient can swallow.

3. Then administer Artemether-Lumefantrine as indicated above or oral quinine if the first drug is not available. However, if a patient has a history of intake of artemether-lumefantrine before complications developed, give quinine tablets 10 mg salt per kg every 8 hours to complete 7 days treatment.

Whenever IV administration of quinine is possible:

Loading dose:

- Quinine 20 mg salt/kg of body weight by infusion over 4 hours, in 5% dextrose saline (5-10ml/kg of body weight depending on the patient’s overall fluid balance).
Maintenance dose:

- Twelve hours after the start of the loading dose, give quinine 10mg salt/kg of body weight in dextrose saline over 4 hours.
- Repeat the same dose of quinine (i.e. 10 mg salt/kg) every 8 hours until the patient can take oral medication.
- Then administer Artemether-Lumefantrine as indicated above or oral quinine if the first drug is not available. However, if a patient has a history of intake of artemether-lumefantrine before complications developed, give quinine tablets 10 mg salt per kg every 8 hours to complete 7 days treatment.
Annex 4. Setting a threshold for malaria epidemic or preparing a norm-chart

Steps:

1. Look at the number of malaria cases at specific health facility or district by month for the past 5 years excluding epidemic years.

2. Determine the 3rd quartile for the monthly series by identifying the 4th highest number from the bottom in each data series (since data is ranked in ascending order). This is the 3rd quartile representing the upper limit of the expected normal number of malaria cases.

3. Plot the 3rd quartile for each data series by months for the 5 year period and join the points with a line. The line represents the upper normal limit of the expected number of cases.

4. Plot the monthly malaria cases that visited a health facility and compare with the third quartile or the norm-chart. If the number is
above the 3rd quartile (upper limit), this is an indication of a possible malaria epidemic.

Example: Number of malaria cases in certain health facility by month for consecutive five years along with the median and the 3rd quartile for each month for the five year is shown in the table below.
### Number of malaria cases per month in each year

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>75</td>
<td>62</td>
<td>51</td>
<td>48</td>
<td>56</td>
<td>45</td>
<td>48</td>
<td>54</td>
<td>72</td>
<td>80</td>
<td>85</td>
<td>74</td>
</tr>
<tr>
<td>2002</td>
<td>67</td>
<td>60</td>
<td>54</td>
<td>49</td>
<td>42</td>
<td>43</td>
<td>42</td>
<td>49</td>
<td>90</td>
<td>104</td>
<td>102</td>
<td>82</td>
</tr>
<tr>
<td>2003</td>
<td>59</td>
<td>47</td>
<td>44</td>
<td>40</td>
<td>37</td>
<td>42</td>
<td>48</td>
<td>50</td>
<td>65</td>
<td>71</td>
<td>73</td>
<td>60</td>
</tr>
<tr>
<td>2004</td>
<td>70</td>
<td>65</td>
<td>57</td>
<td>53</td>
<td>51</td>
<td>53</td>
<td>57</td>
<td>60</td>
<td>63</td>
<td>71</td>
<td>80</td>
<td>77</td>
</tr>
<tr>
<td>2005</td>
<td>82</td>
<td>79</td>
<td>71</td>
<td>61</td>
<td>60</td>
<td>58</td>
<td>63</td>
<td>67</td>
<td>79</td>
<td>95</td>
<td>113</td>
<td>86</td>
</tr>
<tr>
<td>3rd quartile</td>
<td>75</td>
<td>65</td>
<td>57</td>
<td>53</td>
<td>56</td>
<td>53</td>
<td>57</td>
<td>60</td>
<td>79</td>
<td>95</td>
<td>102</td>
<td>82</td>
</tr>
</tbody>
</table>
From the hypothetical and 3rd quartile given in the above table, a graph can be prepared as follows. A second line represents a year report of certain health facility (HF) plotted on a monthly basis to show how current data is compared with the norm-chart.

Fig. a norm-chart showing the pattern of the median and 3rd quartile for the number of malaria cases for certain health facility.
Annex 5. Specimens for laboratory confirmation for epidemic prone disease

<table>
<thead>
<tr>
<th>Suspected disease or condition</th>
<th>Diagnostic test</th>
<th>Specimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholera</td>
<td>Isolate V. cholerae from stool culture and determine 01 serotype using polyvalent antisera for V. cholera 01</td>
<td>Liquid stool or rectal swab</td>
</tr>
<tr>
<td>Diarrhea with blood (shigella dysenteriae type) and other shigellae</td>
<td>Isolate shigella dysenteriae type 1 (SDI) in culture</td>
<td>Stool or rectal swab</td>
</tr>
</tbody>
</table>
### Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

<table>
<thead>
<tr>
<th>Disease</th>
<th>Diagnostic Procedure</th>
<th>Sample Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria</td>
<td>Presence of malaria parasites in blood films for suspected cases</td>
<td>Blood usually from finger-sample</td>
</tr>
<tr>
<td>Measles</td>
<td>Presence of IgM antibodies to measles virus in serum</td>
<td>Serum</td>
</tr>
<tr>
<td>Meningitis</td>
<td>- Microscopic examination of CSF for gram negative diplococci</td>
<td>Cerebral Signal Fluid (CSF)</td>
</tr>
<tr>
<td></td>
<td>- Culture and isolation of N. Meningitis from CSF</td>
<td>- If CSF is not availableblood culture</td>
</tr>
<tr>
<td>Typhoid fever</td>
<td>Blood and stool culture</td>
<td>Stool or blood and</td>
</tr>
</tbody>
</table>
### Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

<table>
<thead>
<tr>
<th>Disease</th>
<th>Test Method</th>
<th>Sample Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemic typhus</td>
<td>ELISA test</td>
<td>Serum</td>
</tr>
<tr>
<td>Yellow fever</td>
<td>Serology test</td>
<td>Serum</td>
</tr>
<tr>
<td>Relapsing fever</td>
<td>ELISA for the presence of yellow fever IgM antibodies</td>
<td>Serum</td>
</tr>
<tr>
<td></td>
<td>Presence barreilla recurrenti in blood films for suspected cases</td>
<td>Blood from finger pick</td>
</tr>
</tbody>
</table>
## Annex 6. Recommended case definitions for use by health facilities and in the community

<table>
<thead>
<tr>
<th>Disease</th>
<th>Use for reporting suspected priority diseases by health facilities</th>
<th>Use for community level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholera</td>
<td>Any person 5 years of age or more who develops severe dehydration or dies from acute watery diarrhea.</td>
<td>Any person 5 years of age or more with lots of watery diarrhea</td>
</tr>
<tr>
<td>Diarrhea with blood (shigella)</td>
<td>Any person with diarrhea and visible blood in the stool</td>
<td>Any person with diarrhea and visible blood in the stool</td>
</tr>
<tr>
<td>Measles</td>
<td>Any person with fever and maculo papular (non- vesicular) generalized rash and cough,</td>
<td>Any person with fever and rash</td>
</tr>
<tr>
<td>Disease</td>
<td>Symptoms/Signs</td>
<td>Death Criteria</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------------------</td>
</tr>
<tr>
<td>Coryza or Conjunctivitis</td>
<td>An individual who is suspected of having measles after the onset of coryza or conjunctivitis. Any person in whom a clinician suspects measles. A measles death is a death occurring within 30 days of the onset of the rash.</td>
<td></td>
</tr>
<tr>
<td>Typhoid fever</td>
<td>Fever, chills, gradually increasing and persisting headache, rash, abdominal pain, diarrhea or constipation, delirium, and prostration.</td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td>Any person with sudden onset of fever (rectal &gt; 38.5°C or axillary 38°C) and one of the following signs: neck stiffness, altered consciousness or other meningeal signs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any person with fever and neck stiffness.</td>
<td></td>
</tr>
<tr>
<td>Disease</td>
<td>Symptoms</td>
<td>Criteria</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Relapsing fever</td>
<td>Fever lasting 2-9 days and with afebrile period of 2-4 days</td>
<td>Any person with fever that relapses after a febrile periods</td>
</tr>
<tr>
<td>Epidemic Typhus</td>
<td>Sudden onset of headache, chills, prostration, fever and general pains possibly with macular eruption that initially appear on the trunk followed by a spread to other body parts except the face, the soles and palms</td>
<td>Any person with sudden onset of headache and fever with chills, general pains, with or without rash</td>
</tr>
<tr>
<td>Malaria</td>
<td>Uncomplicated malaria Any person with fever with headache, back pain, chills, sweats, myalgia, nausea, and vomiting diagnosed clinically as</td>
<td>Any person with fever or fever with headache, back pain, chills, sweats, myalgia, nausea and vomiting.</td>
</tr>
<tr>
<td>Disease</td>
<td>Definition</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>Confirmed uncomplicated malaria&lt;br&gt;Any person with fever or fever with headache, back pain, chills, sweats, myalgia,</td>
<td></td>
</tr>
<tr>
<td>Yellow fever</td>
<td>Any person with sudden onset of high fever (&gt;39°C rectal or 38°C axillary) followed by jaundice with in two weeks of onset of first symptoms&lt;br&gt;Any person with fever and yellowing in the white part of the eyes or yellowing of the skin.</td>
<td></td>
</tr>
</tbody>
</table>
### Annex 7. IDS case-based surveillance reporting form

<table>
<thead>
<tr>
<th>Disease</th>
<th>Reporting health facility:</th>
<th>Rep</th>
<th>tting Woreda/zone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholera</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dracunculiasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neonatal Tetanus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plague</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral hemorrhagic Fever</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>yellow Fever</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others/Special</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Date of form received at the national level:** / / (Day/Month/Year)

**Name of patient:**

**Date of birth (DOB):** / / (Day/Month/Year)  
**Age (if DOB unknown):**

<table>
<thead>
<tr>
<th>Year</th>
<th>Month (if&lt;12)</th>
<th>Day (NNT only)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sex:**  
M = Male  
F = Female

**Patient's Address:**

<table>
<thead>
<tr>
<th>Urban</th>
<th>Rural</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Kebele:**

**Woreda:**

**Zone:**

**Region:**
<table>
<thead>
<tr>
<th><strong>Locating Information:</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>If applicable or if the patient is neonate or child, please write full name of mother and father of the patient</td>
<td></td>
</tr>
<tr>
<td><strong>Date seen at Health Facility:</strong></td>
<td><strong>Date Health Facility Notified woreda/Zone:</strong></td>
</tr>
<tr>
<td>/ /</td>
<td>/ /</td>
</tr>
<tr>
<td><strong>Number of vaccine doses received:</strong></td>
<td>For cases of Measles, NT (TT in mother), yellow Fever, and Meningitis (For Measles, TT, YF-by card &amp; for Meningitis, by history)</td>
</tr>
<tr>
<td>/ /</td>
<td>/ /</td>
</tr>
<tr>
<td><strong>Date of last vaccination:</strong></td>
<td></td>
</tr>
<tr>
<td>/ /</td>
<td></td>
</tr>
<tr>
<td><strong>Outcome:</strong></td>
<td><strong>Blank variable #1 of the case:</strong></td>
</tr>
<tr>
<td>1= Alive</td>
<td></td>
</tr>
<tr>
<td>2= Dead</td>
<td>2= Inpatient</td>
</tr>
<tr>
<td>3= Unknown</td>
<td></td>
</tr>
</tbody>
</table>
### Final classification of case

<table>
<thead>
<tr>
<th></th>
<th>1=Confirmed</th>
<th>2= Probable</th>
<th>3= Discarded</th>
<th>4= Suspect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person completing the form: Name:</td>
<td></td>
<td></td>
<td></td>
<td>Signature:</td>
</tr>
<tr>
<td>Date form sent to Woreda/zone:</td>
<td>/</td>
<td>/ (Day/month/Year)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
If Lab Specimen Collected

*For Health Facility: If lab specimen is collected, complete the following information and send a copy of this form to the lab with the specimen.*

<table>
<thead>
<tr>
<th>Date of specimen collection:</th>
<th>/ /</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of specimen:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stool</td>
</tr>
<tr>
<td>Date specimen received to lab:</td>
<td>/ /</td>
</tr>
<tr>
<td>ID Number:</td>
<td></td>
</tr>
<tr>
<td>For the lab: Complete this section and return the form to Woreda/zone health facility team or clinician</td>
<td></td>
</tr>
<tr>
<td>Date lab specimen:</td>
<td>/ /</td>
</tr>
<tr>
<td>Specimen condition:</td>
<td>Adequate</td>
</tr>
<tr>
<td>Disease/condition:</td>
<td></td>
</tr>
<tr>
<td>Type of Test:</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td></td>
</tr>
<tr>
<td><em>malaria</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>P. falciparum</em></td>
</tr>
<tr>
<td><em>Cholera (culture)</em></td>
<td></td>
</tr>
</tbody>
</table>
### Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

<table>
<thead>
<tr>
<th>Condition</th>
<th>Method</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholera direct exam; specify the method used:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningitis: N Meningitidis</td>
<td>Culture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gram stain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningitis: S pneumonia</td>
<td>Culture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gram stain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningitis: H influenza</td>
<td>Culture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gram stain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shigella Dysenteriae</td>
<td>Culture</td>
<td>Type</td>
<td>/Type1</td>
<td>/Other types</td>
</tr>
<tr>
<td></td>
<td>Widal (&quot;0&quot; &gt; 1:160)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

209
<table>
<thead>
<tr>
<th>Test Type</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Culture</td>
<td></td>
</tr>
<tr>
<td>Stool culture</td>
<td></td>
</tr>
<tr>
<td><strong>Epidemic typhus: serum test</strong> (0X19)</td>
<td></td>
</tr>
<tr>
<td>Viral Detection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yellow fever (IgM)</td>
</tr>
<tr>
<td></td>
<td>Measles (IgM)</td>
</tr>
<tr>
<td></td>
<td>Rubella (IgM)</td>
</tr>
<tr>
<td></td>
<td>RVF (IgM)</td>
</tr>
<tr>
<td></td>
<td>Ebola (IgM)</td>
</tr>
<tr>
<td>Other lab test (specify)</td>
<td>Results:</td>
</tr>
<tr>
<td>Date lab sent results to Woreda/zone/health facility:</td>
<td>/ /</td>
</tr>
<tr>
<td>Name of lab sending results:</td>
<td></td>
</tr>
<tr>
<td>Other pending results:</td>
<td></td>
</tr>
<tr>
<td>Name of lab technician sending the results:</td>
<td>Signature</td>
</tr>
<tr>
<td>Date Woreda/zone receive lab results:</td>
<td>/ / Woreda/zone:</td>
</tr>
<tr>
<td>Date lab results sent to health facility by woreda/zone:</td>
<td>/</td>
</tr>
<tr>
<td>Date lab results received at the health facility:</td>
<td>/</td>
</tr>
</tbody>
</table>
Annex 8. Case Study: Epidemic preparedness and response plan for Measles outbreak

This plan adopted from WHO guidelines for Epidemic preparedness and response for Measles outbreak, Geneva, Switzerland, May 1999. It describes the way the plan should be designed and what issue should be dealt to have a comprehensive plan. This can be also taken as a sample to prepare epidemic preparedness and response plan in the context of specific disease entity using the same steps (see annex 1).

Part I. The organism and Disease
1.1 The nature and magnitude of the problem
Measles ranks as one of the leading causes of childhood mortality in the world. Before measles vaccine became available, virtually all individuals contracted measles with an estimated 130 million cases each year. Humans are the only natural host. Measles is a highly communicable infection. In Ethiopia,
1.2 The organism
Measles virus is a paramyxovirus of a single serological type.

1.3 The disease (pathogenesis and clinical problems)
The incubation period usually lasts 10 days (with a range from 7 to 18 days) from exposure to the onset of fever. The disease is characterised by prodromal fever, conjunctivitis, coryza, cough and the presence of Koplik spots (reddish spots with a white centre) on the buccal mucosa. A characteristic red rash appears on the third to seventh day beginning on the face, becoming generalised and lasting 4-7 days. Measles can also lead to life-long disabilities, including blindness, brain damage and deafness.

Clinical case definition:
Any person in whom a clinician suspects measles infection

OR
Any person with fever, and maculopapular rash (i.e. non-vesicular), and cough, coryza (i.e. runny nose) or conjunctivitis (i.e. red eyes)

1.4 Transmission and immunity
Transmission is airborne, by droplet spread or by direct contact with the nasal and throat secretions of infected persons. And also it is communicable from slightly before the prodromal period to four days after the appearance of the rash.
Natural infection produces a lifelong immunity. Measles vaccine induces long-term and probably lifelong immunity in most individuals.

1.5 Treatment

1.5.1. Diagnosis: use of standard cased definition (as a clinical case definition in part 1.3)

1.5.2. Clinical assessment: Children must be examined for the following signs and symptoms to
ensure that those with severe complications are properly treated:

Ask if the child has had:
- an inappropriate change in the level of consciousness, feeding or drinking
- cough, convulsions, diarrhoea, ear pain
- discharge from eyes or loss of vision

Examine the child for:
- rapid pulse, wasting, sore red mouth
- dehydration (thirst, sunken eyes, skin pinch goes back slowly)
- pneumonia (rapid breathing, chest indrawing)
- ear infection (draining pus, red/immobile eardrum)
- eye disease (pus; corneal ulcer, perforation, clouding)

1.5.3. **Classification for management**: since case management depends on the severity of disease, the degree of severity of the case must be stated:
uncomplicated measles: a child with measles and none of the signs or symptoms of complicated disease

complicated measles: a child with measles and at least one of the signs or symptoms of complicated disease as per following table.

Complications of measles

<table>
<thead>
<tr>
<th>Acute Complication</th>
<th>Later complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhoea</td>
<td>Increased susceptibility to other infection</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>Blindness</td>
</tr>
<tr>
<td>Laryngo-tracheobronchitis</td>
<td>Sub acute scelorsing encephalitis (SSPE)</td>
</tr>
<tr>
<td>Otitis media</td>
<td></td>
</tr>
<tr>
<td>Malnutrition</td>
<td></td>
</tr>
<tr>
<td>Corneal ulceration and blindness( due to Vitamin A deficiency)</td>
<td></td>
</tr>
<tr>
<td>Stomatitis</td>
<td></td>
</tr>
<tr>
<td>Acute encephalitis</td>
<td></td>
</tr>
</tbody>
</table>
1.5.4. Case management (see measles specific management section in chapter 5)

Part II. Prevention and Control
2.1 Phases of measles control
The introduction of measles vaccine into routine immunization programmes results in a marked reduction in incidence of the disease and its associated morbidity and mortality.

There are three sequential phases for measles immunization programmes as indicated in the figure below.
- measles control phase
- measles outbreak prevention phase
- measles elimination phase
Fig 3.3. Sequential Phases for Measles programmes

Sequential phases for Measles Program
2.2 Measles control phase
The main strategy in this phase is increasing immunization/vaccine coverage, when high levels of vaccine coverage are attained (i.e. vaccine coverage >80%), measles incidence decreases and the intervals between outbreaks are lengthened (e.g., 4-8 years) when compared to those observed during the pre-vaccine era (e.g., 2-4 years)

2.3 Outbreak prevention phase
Once measles have been drastically and persistently reduced through a sustained increase in immunization coverage, outbreak prevention strategies should be implemented aiming at the prevention of periodic measles outbreaks. These strategies include improved surveillance in order to understand the changing epidemiology of the disease (e.g., changes in the age distribution of cases, etc.) and in order to identify populations at higher risk areas. (i.e. low immunization coverage, poor socio-economic and educational status, overcrowding, migration areas, Poor access to health facilities
and vitamin A deficiency) and higher risk groups (i.e. the young, particularly those less than one year old, the severely malnourished, infants and children of HIV infected women, other immuno-compromised children, displaced populations such as refugees living in camps or population migrating to urban and peri-urban areas, and certain ethnic and religious groups who may have poor access to, or refuse immunization.) And also it is possible to predict outbreaks and to prevent them by timely immunization of susceptible individuals in populations at higher risk and by improving overall levels of vaccine coverage in the population. If an outbreak is anticipated, supplementary immunization activities may be considered.

2.4 Measles elimination phase

Measles eradication is defined as the world-wide interruption of transmission of the virus, and represents the sum of successful elimination efforts in all countries and regions. This will be achieved
through maintaining the number of susceptible individuals in the population below the critical number that helps to sustain transmission of the measles virus.

The strategies should:

- Drastically and speedily reduce the number of susceptible individuals in those age-groups where most susceptible individuals have accumulated and where the nature of contact among them facilitates virus transmission.

- Maintain the build-up of susceptible individuals at very low levels by immunising a large proportion (>95%) of each new birth cohort.

- Implement additional vaccination activities to periodically protect susceptible individuals who have accumulated
Part III. Epidemic Control

3.1 Management
When an outbreak occurs that has not been predicted, or could not be prevented, the response needs to be rapid, since measles is highly infectious and spreads rapidly. This supported by clearly defining surveillance system and outbreak threshold.

3.2 Detection
Detection of an outbreak relies on the ability of the responsible authority (Ministry of Health/Regional or District Health office) to recognise an increase in measles cases significantly above the number normally expected. This recognition is simpler if a routine surveillance system collects either summary or case-based information on clinical and confirmed cases of measles. The availability of such data allows for the establishment of background activity levels and the establishment of a local outbreak (or
epidemic) threshold. This threshold value is usually a number of cases in a defined period in excess of (a predetermined) expected number. The attainment of a threshold value should be considered as signalling an outbreak and should trigger specific responses.

3.3 Confirmation
When an outbreak is suspected:

- A preliminary case investigation must be carried out to confirm the diagnosis, assess the extent of the outbreak and identify the population at risk. This is best done by health workers using a suspected measles investigation form, seeking details on cases (e.g. clinical syndrome and immunization status) and contacts.

- It is important that blood samples be collected from the initial 10 reported cases of an outbreak, to confirm or not whether measles virus is the cause of the outbreak.
• hen blood samples should be taken and sent to central/national laboratories, which allows for confirmation of an outbreak.

3.4 Response

3.4.1 Planning a response
In case of a confirmed epidemic in a population, it is important to plan a systematic response based on the available data. Outbreaks provide an opportunity to collect data, identify problems and adjust strategies accordingly. This is best done in consultation with other key players. The convening of a response team (e.g. epidemic committee, rapid epidemic response team) is essential to ensure quality decisions and coordination. The main areas to be dealt with are:

• definition of and agreement on response
• management of response
• resources for response
• public information
• post-outbreak activities
• Prediction of, and preparedness for, further outbreaks.

Epidemic committee
The epidemic committee may include the following representative:
• National/Regional/ District governmental officials
• The Ministry of Health/ Regional or District Health Office (experts on communicable diseases, EPI, drug supply)
• Hospitals (clinicians and nurses)
• Laboratories
• NGOs
• Police and armed forces (if possible)
• Community leaders and/or representatives
• Others as appropriate

The responsibilities of the epidemic response team are to:
• Meet in the absence of an epidemic to predict and plan for epidemics
Estimate and identify resources and procedures for preventive mass vaccination campaigns

Estimate and identify additional resources needed for rapid epidemic response

Ensure the availability of staff and training for epidemic response

Analyse epidemiological information concerning the evolution of an epidemic

Plan control and response strategies in the light of overall programme objectives

Establish clear lines of responsibility for planned actions

Meet regularly to review data and implemented measures

Communicate with the general public and the media

Evaluate the response

Evaluate the immunization programme

Produce a detailed report on outbreak response activities

Make recommendations on changes to immunization strategy and programme
3.4.2 Definition and agreement on response
The main activities during the response to an outbreak will depend on the phase of the immunization programme. The activities to be implemented as a priority during all measles outbreaks will be:

- to prevent measles complications and deaths through early and effective case management
- to review epidemiological data and immunization programme in order to identify the cause(s) of the outbreak
- to increase public awareness of measles infection, treatment and prevention through immunization
- to strengthen existing routine immunization programmes, with particular attention to the identification of high-risk areas.

3.4.3 Management of response
Once a clear strategy has been defined, it is necessary to mobilise and manage the resources
required for the response. These resources will need to be mobilised in a co-ordinated fashion.

3.4.4 Public information

When an outbreak is declared, there is likely to be widespread public concern and media attention. It is important to keep the public informed about the outbreak and the outbreak response. Public information can be transmitted by a number of simple means, either directly to the community via schools or community meetings, or via the mass media such as radio, newspapers and television.

Simple, clear public information material can help to:

- allay fears
- convey public health messages regarding appropriate treatment of cases and immunization.

It is important that such material:

- give information on the natural history of measles infection, the care of a child with measles and the signs and symptoms that should prompt a parent to seek expert advice
encourage parents whose children have had a recent onset of rash and fever to notify health workers
give clear information on the age for immunization and on the locations and time-schedule of any vaccination activities.

3.4.6 Post-outbreak activities
After an outbreak, the Epidemic committee must carry out a thorough evaluation of the following:
- cause of the epidemic
- surveillance of measles and detection of the outbreak
- preparedness for the epidemic
- management of the epidemic
- immunization programme goals and operations

The findings of this evaluation should be documented in a written report containing clear recommendations regarding:
- epidemiological characteristics of the epidemic
• Surveillance (assess the surveillance system; recommend actions to enhance measles surveillance in the affected areas)
• Preparedness/recommend action to improve outbreak response
• Immunization activities and strategies to increase coverage and cover high-risk areas.
GLOSSARY

**Attack rate:** a variant of an incident rate, applied to a narrowly defined population observed for a limited period of time, such as during an epidemic.

**Case definition:** a set of standard criteria for deciding whether a person has a particular disease or health related condition, by specifying clinical criteria and limitations on time, place and person.

**Epidemic:** The occurrence of more cases of disease than expected in a given area or among a specific group of people over a specified period of time.

**Epidemic curve:** a histogram that shows the course of a disease epidemic or epidemic by plotting the number of cases by time of onset.

**Host:** a person or other living organism that offers subsistence or lodgment to an infectious agent under natural conditions.
Manual on Investigation and Management of Epidemic Prone Diseases in Ethiopia

**Host factor:** an intrinsic factor (age, race, sex, behaviors, etc.) which influences an individual’s exposure, susceptibility, or response to the causative organism.

**Immunity:** resistance usually associated with the presence of antibodies or cells having a specific action on the microorganism concerned with a particular infectious disease or on its toxin.

**Inapparent infection:** The presence of infection in a host without recognizable clinical signs or symptoms.

**Incubation period:** a period of sub-clinical or inapparent pathologic changes following exposure, ending with the onset of symptoms of infectious disease.

**Infection:** The entry and development or multiplication of an infectious agent in the body of persons or animals.
**Infectious agent:** an organism (virus, rickettsia, bacteria, fungus, protozoan or helminth) that is capable of producing infection or infectious disease. Mixed epidemic is the type of epidemic usually begins with a common source of infectious agent with subsequent propagated spread.

**Nosocomial infection:** those infections that were neither present nor incubating at the time the patient was admitted.

**Pandemic:** an epidemic occurring over a very wide area (several countries or continents) and usually affecting a large proportion of the population.

**Pathogenicity:** the proportion of persons infected, after exposure to a causative agent, who then develop a clinical disease.

**Public Health Surveillance:** the systematic collection, analysis, interpretation, and dissemination of health data on an ongoing base, to gain
knowledge of the pattern of disease occurrence and potential in a community, in order to control and prevent disease in the community.

**Reservoir**: the habit in which an infectious agent normally lives, growth and multiply; reservoirs include human reservoir, animal reservoir, and environmental reservoir.

**Spot map**: a map that indicates the location of each case of a rare disease or epidemic by a place that is potentially a relevant to the health event being investigated, such as where each case lived or worked.

**Susceptible host**: a person or animal not possessing sufficient resistance against a particular pathogenic agent to prevent contracting infection or disease when exposed to the agent.
Virulence: the proportion of persons with clinical disease, who after becoming infected, becomes severely ill or die.